Erythema Ab Igne: A Clinical Review

Article Type
Changed
Thu, 04/27/2023 - 12:21
Display Headline
Erythema Ab Igne: A Clinical Review

Erythema ab igne (EAI)(also known as toasted skin syndrome) was first described in the British Journal of Dermatology in the 20th century, 1 though it was known by physicians long before. Reticular netlike skin changes were seen in association with patients who spent extended time directly next to a heat source. This association led to the name of this condition, which literally means “redness by fire.” Indeed, EAI induced by chronic heat exposure has been described across the world for centuries. For example, in the cold regions of northern China, people used to sleep on beds of hot bricks called kang to stay warm at night. The people of India’s Kashmir district carried pots of hot coals called kangri next to the skin under large woven shawls to stay warm. In the past, Irish women often spent much time by a turf- or peat-burning fire. Chronic heat exposure in these cases can lead not only to EAI but also to aggressive types of cancer, often with a latency of 30 years or more. 2

More recently, the invention of home central heating led to a stark decrease in the number of cases associated with combustion-based heat, with a transition to etiologies such as use of hot water bottles, electric blankets, and electric space heaters. Over time, technological advances led to ever-increasing potential causes for EAI, such as laptops or cell phones, car heaters and heated seats, heated blankets,3,4 infrared lamps for food, and even medical devices such as ultrasound-based heating products and convective temperature management systems for hospitalized patients. As technology evolves, so do the potential causes of EAI, requiring clinicians to diagnose and deduce the cause through a thorough social and medical history as well as a workup on the present illness with considerations for the anatomical location.5-7 Herein, we describe the etiology of EAI, diagnosis, and treatment options.

Erythema ab igne secondary to use of a space heater nightly for 6 months.
FIGURE 1. Erythema ab igne secondary to use of a space heater nightly for 6 months.

Clinical Characteristics

Erythema ab igne begins as mild, transient, and erythematous macules and patches in a reticular pattern that resolve minutes to hours after removal of the heat source. With weeks to months of continued or repeated application of the heat source, the affected area eventually becomes hyperpigmented where there once was erythema (Figures 1 and 2). Sometimes papules, bullae, telangiectasia, and hyperkeratosis also form. The rash usually is asymptomatic, though pain, pruritus, and dysesthesia have been reported.7 Dermoscopy of EAI in the hyperpigmented stage can reveal diffuse superficial dark pigmentation, telangiectasia, and mild whitish scaling.8 Although the pathogenesis has remained elusive over the years, lesions do seem to be mostly associated with cumulative exposure to heat rather than length of exposure.7

Biopsy-proven erythema ab igne in a patient with darker skin.
FIGURE 2. Biopsy-proven erythema ab igne in a patient with darker skin.

Etiology of EAI

Anatomic Location—The affected site depends on the source of heat (Table). Classic examples of this condition include a patient with EAI presenting on the anterior thighs after working in front of a hot oven or a patient with chronic back pain presenting with lower-back EAI secondary to frequent use of a hot water bottle or heating pad.7 With evolving technology over the last few decades, new etiologies have become more common—teenagers are presenting with anterior thigh EAI secondary to frequent laptop use2-29; patients are holding warm cell phones in their pant pockets, leading to unilateral geometric EAI on the anterior thigh (front pocket) or buttock (back pocket)30; plug-in radiators under computer desks are causing EAI on the lower legs31-34; and automobile seat heaters have been shown to cause EAI on the posterior legs.5,35-37 Clinicians should consider anatomic location a critical clue for etiology.

Etiologic Considerations and Possible Comorbidities Based on Anatomic Location of Erythema Ab Igne

Social History—There are rarer and more highly specific causes of EAI than simple heat exposure that can be parsed from a patient’s social history. Occupational exposure has been documented, such as bakers with exposure to ovens, foundry workers with exposure to heated metals, or fast-food workers with chronic exposure to infrared food lamps.6,7 There also are cultural practices that can cause EAI. For example, the practice of cupping with moxibustion was shown to create a specific pattern in the shape of the cultural tool used.38 When footbaths with Chinese herbal remedies are performed frequently with high heat, they can lead to EAI on the feet with a linear border at the ankles. There also have been reports of kotatsu (heated tables in Japan) leading to lower-body EAI.39,40 These cultural practices also are more common in patients with darker skin types, which can lead to hyperpigmentation that is difficult to treat, making early diagnosis important.7

Medical History—Case reports have shown EAI caused by patients attempting to use heat-based methods for pain relief of an underlying serious disease such as cancer, bowel pathology (abdominal EAI), spinal disc prolapse (midline back EAI),41 sickle cell anemia, and renal pathology (posterior upper flank EAI).6,7,40-49 Patients with hypothyroidism or anorexia have been noted to have generalized EAI sparing the face secondary to repeated and extended hot baths or showers.50-53 One patient with schizophrenia was shown to have associated thermophilia due to a delusion that led the patient to soak in hot baths for long periods of time, leading to EAI.54 Finally, all physicians should be aware of iatrogenic causes of EAI, such as use of warming devices, ultrasound-based warming techniques, and laser therapy for lipolysis. Inquire about the patient’s surgical history or intensive care unit stays as well as alternative medicine or chiropractic visits. Obtaining a history of medical procedures can be enlightening when an etiology is not immediately clear.7,55,56

Diagnosis

Erythema ab igne is a clinical diagnosis based on recognizable cutaneous findings and a clear history of moderate heat exposure. However, when a clinical diagnosis of EAI is not certain (eg, when unable to obtain a clear history from the patient) or when malignant transformation is suspected, a biopsy can be performed. Pathologically, hematoxylin and eosin staining of EAI classically reveals dilated small vascular channels in the superficial dermis, hence a clinically reticular rash; interface dermatitis clinically manifesting as erythema; and pigment incontinence with melanin-laden macrophages consistent with clinical hyperpigmentation. Finally, for unclear reasons, increased numbers of elastic fibers classically are seen in biopsies of EAI.7

 

 

Differential Diagnosis

The differential diagnosis for a reticular patch includes livedo reticularis (Figure 3), which usually manifests as a more generalized rash in patients with chronic disease or coagulopathy such as systemic lupus erythematosus, cryoglobulinemia, or Raynaud phenomenon. When differentiating EAI from livedo reticularis or cutis marmorata, consider that both alternative diagnoses are more vascular appearing and are associated with cold exposure rather than heat exposure. In cases that are less reticular, livedo racemosa can be considered in the differential diagnosis. Finally, poikiloderma of Civatte can be reticular, particularly on dermoscopy, but the distribution on the neck with submental sparing should help to distinguish it from EAI unless a heat source around the neck is identified while taking the patient’s history.7

Livedo reticularis in a patient with chronic autoimmune disease.
FIGURE 3. Livedo reticularis in a patient with chronic autoimmune disease.

In babies, a reticular generalized rash is most likely to be cutis marmorata (Figure 4), which is a physiologic response to cold exposure that resolves with rewarming of the skin. A more serious condition—cutis marmorata telangiectatica congenita (Figure 5)—usually is present at birth, most frequently involves a single extremity, and notably does not resolve with rewarming. This is an important differential for EAI in children because it can be associated with vascular and neurologic anomalies as well as limb asymmetry. Finally, port-wine stains can sometimes be reticular in appearance and can mimic the early erythematous stages of EAI. However, unlike the erythematous stage of EAI, the port-wine stains will be present at birth.7

Cutis marmorata in a 1-month-old infant.
FIGURE 4. Cutis marmorata in a 1-month-old infant.

Emerging in 2020, an important differential diagnosis to consider is a cutaneous manifestation of COVID-19 infection. An erythematous, reticular, chilblainlike or transient livedo reticularis–like rash has been described as a cutaneous manifestation of COVID-19. Although the pathophysiology is still being elucidated, it is suspected that this is caused by a major vaso-occlusive crisis secondary to COVID-19–induced thrombotic vasculopathy. Interestingly, the majority of patients with this COVID-related exanthem also displayed symptoms of COVID-19 (eg, fever, cough) at the time of presentation,57-60 but there also have been cases in patients who were asymptomatic or mildly symptomatic.60

Cutis marmorata telangiectatica congenita in a 3-month-old infant.
FIGURE 5. Cutis marmorata telangiectatica congenita in a 3-month-old infant.

In some cases, EAI is an indication to screen for an underlying disease. For example, uncontrolled pain is an opportunity to improve interventions such as modifying the patient’s pain-control regimen, placing a palliative care pain consultation, or checking if the patient has had age-appropriate screenings for malignancy. New focal pain in a patient with a prior diagnosis of cancer may be a sign of a new metastasis. A thermophilic patient leaves opportunity to assess for underlying medical causes such as thyroid abnormalities or social/psychological issues. Geriatric patients who are diagnosed with EAI may need to be assessed for dementia or home safety issues. Patients with a history of diabetes mellitus can unknowingly develop EAI on the lower extremities, which may signal a need to assess the patient for peripheral neuropathy. Patients with gastroparesis secondary to diabetes also may develop EAI on the abdomen secondary to heating pad use for discomfort. These examples are a reminder to consider possible secondary comorbidities in all diagnoses of EAI.7 

Prognosis

Although the prognosis of EAI is excellent if caught early, failure to diagnose this condition can lead to permanent discoloration of the skin and even malignancy.6 A rare sequela includes squamous cell carcinoma, most commonly seen in chronic cases of the lower leg, which is likely related to chronic inflammation of the skin.61-65 Rare cases of poorly differentiated carcinoma,66 cutaneous marginal zone lymphoma,67 and Merkel cell carcinoma68 have been reported. Patients diagnosed with EAI should receive normal periodic surveillance of the skin based on their medical history, though the physician should have an increased suspicion and plan for biopsy of any nodules or ulcerations found on the skin of the affected area.7

Treatments

Once the diagnosis of EAI is made, treatment starts with removal of the heat source causing the rash. Because the rash usually is asymptomatic, further treatment typically is not required. The discoloration can resolve over months or years, but permanent hyperpigmentation is not uncommon. If hyperpigmentation persists despite removal of the heat source and the patient desires further treatment for discoloration, there are few treatment options, none of which are approved by the US Food and Drug Administration for this condition.7 There is some evidence for the use of Nd:YAG lasers to reduce hyperpigmentation in EAI.69 There have been some reports of treatment using topical hydroquinone and topical tretinoin in an attempt to lighten the skin. If associated hyperkeratosis or other epithelial atypia is present, the use of 5-fluorouracil may show some improvement.70 One case report has been published of successful treatment with systemic mesoglycan and topical bioflavonoids.71 It also is conceivable that medications used to treat postinflammatory hyperpigmentation may be helpful in this condition (eg, kojic acid, arbutin, mild topical steroids, azelaic acid). Patients with darker skin may experience permanent discoloration and may not be good candidates for alternative treatments such as laser therapy due to the risk for inducible hyperpigmentation.7

Conclusion

No matter the etiology, EAI usually is a benign skin condition that is treated by removal of the causative heat source. Once a diagnosis is made, the clinician must work with the patient to determine the etiology. Care must be taken to ensure that there are no underlying signs, such as chronic pain or psychiatric illness, that could point to associated conditions. Rarely, sequalae such as cancers have been documented in areas of chronic EAI. Once the heat source is identified and removed, any remaining hyperpigmentation usually will self-resolve over months to years, though this may take longer in patients with darker skin types. If more aggressive treatment is preferred by the patient, laser therapy, topical medications, and oral over-the-counter vitamins have been tried with minimal responses. 

References
  1. Perry. Case of erythema ab igne. Br J Dermatol. 1900;xxiii:375.
  2. Bose S, Ortonee JP. Diseases affected by heat. In: Parish LC, Millikan LE, Amer M, et al. Global Dermatology Diagnosis and Management According to Geography, Climate, and Culture. Springer-Varlag; 1994:83-92.
  3. Leal-Lobato MM, Blasco-Morente G. Electric blanket induced erythema ab igne [in Spanish]. Semergen. 2015;41:456-457. doi:10.1016/j.semerg.2014.12.008
  4. Huynh N, Sarma D, Huerter C. Erythema ab igne: a case report and review of the literature. Cutis. 2011;88:290-292.
  5. Kesty K, Feldman SR. Erythema ab igne: evolving technology, evolving presentation. Dermatol Online J. 2014;20. doi:10.5070/D32011024689
  6. Miller K, Hunt R, Chu J, et al. Erythema ab igne. Dermatol Online J. 2011;17:28.
  7. Smith ML. Environmental and sports-related skin diseases. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Elsevier; 2018:1569-1594.
  8. Errichetti E, Stinco G. Dermoscopy in general dermatology: a practical overview. Dermatol Ther (Heidelb). 2016;6:471-507. doi:10.1007/s13555-016-0141-6
  9. Guarneri C, Tchernev G, Wollina U, et al. Erythema ab igne caused by laptop computer. Open Access Maced J Med Sci. 2017;5:490-492. doi:10.3889/oamjms.2017.137
  10. Arnold AW, Itin PH. Laptop computer-induced erythema ab igne in a child and review of the literature. Pediatrics. 2010;126:E1227-E1230. doi:10.1542/peds.2010-1390
  11. Dickman J, Kessler S. Unilateral reticulated patch localized to the anterior thigh. JAAD Case Rep. 2018;4:746-748. doi:10.1016/j.jdcr.2018.06.007
  12. Boffa MJ. Laptop computer-induced erythema ab igne on the left breast. Cutis. 2011;87:175-176.
  13. Li K, Barankin B. Cutaneous manifestations of modern technology use. J Cutan Med Surg. 2011;15:347-353. doi:10.2310/7750.2011.10053
  14. Riahi RR, Cohen PR. Laptop-induced erythema ab igne: report and review of literature. Dermatol Online J. 2012;18:5.
  15. Andersen F. Laptop-thighs--laptop-induced erythema ab igne [in Danish]. Ugeskr Laeger. 2010;172:635.
  16. Jagtman BA. Erythema ab igne due to a laptop computer. Contact Dermatitis. 2004;50:105. doi:10.1111/j.0105-1873.2004.0295g.x
  17. Olechowska M, Kisiel K, Ruszkowska L, et al. Erythema ab igne (EAI) induced by a laptop computer: report of two cases. J Dtsch Dermatol Ges. doi:10.1111/j.1610-0387.2014.12387
  18. Nayak SUK, Shenoi SD, Prabhu S. Laptop induced erythema ab igne. Indian J Dermatol. 2012;57:131-132. doi:10.4103/0019-5154.94284
  19. Salvio AG, Nunes AJ, Angarita DPR. Laptop computer induced erythema ab igne: a new presentation of an old disease. An Bras Dermatol. 2016;91:79-80. doi:10.1590/abd1806-4841.20165139
  20. Schummer C, Tittelbach J, Elsner P. Right-sided laptop dermatitis [in German]. Dtsch Med Wochenschr. 2015;140:1376-1377. doi:10.1055/s-0041-103615
  21. Manoharan D. Erythema ab igne: usual site, unusual cause. J Pharm Bioallied Sci. 2015;7(suppl 1):S74-S75. doi:10.4103/0975-7406.155811
  22. Giraldi S, Diettrich F, Abbage KT, et al. Erythema ab igne induced by a laptop computer in an adolescent. An Bras Dermatol. 2011;86:128-130. doi:10.1590/S0365-05962011000100018
  23. Secher LLS, Vind-Kezunovic D, Zachariae COC. Side-effects to the use of laptop computers: erythema ab igne. Dermatol Reports. 2010;31:E11. doi:10.4081/dr.2010.e11
  24. Botten D, Langley RGB, Webb A. Academic branding: erythema ab igne and use of laptop computers. CMAJ. 2010;182:E857. doi:10.1503/cmaj.091868
  25. Bilic M, Adams BB. Erythema ab igne induced by a laptop computer. J Am Acad Dermatol. 2004;50:973-974. doi:10.1016/j.jaad.2003.08.007
  26. Fu LW, Vender R. Erythema ab igne caused by laptop computer gaming - a case report. Int J Dermatol. 2012;51:716-717. doi:10.1111/j.1365-4632.2011.05033.x
  27. Levinbook WS, Mallett J, Grant-Kels JM. Laptop computer-associated erythema ab igne. Cutis. 2007;80:319-320.
  28. Mohr MR, Scott KA, Pariser RM, et al. Laptop computer-induced erythema ab igne: a case report. Cutis. 2007;79:59-60.
  29. Cantor AS, Bartling SJ. Laptop computer-induced hyperpigmentation. Dermatol Online J. 2018;24:13030/qt6k37r9wm.
  30. Kaptanog˘lu AF, Mullaaziz D. Erythema ab igne in the palmar area induced by smart phone: case report. Turkiye Klin J Med Sci. 2015;35:284-286. doi:10.5336/medsci.2015-46976
  31. Redding KS, Watts AN, Lee J, et al. Space heater-induced bullous erythema ab igne. Cutis. 2017;100:E9-E10.
  32. Goorland J, Edens MA, Baudoin TD. An emergency department presentation of erythema ab igne caused by repeated heater exposure. J La State Med Soc. 2016;168:33-34.
  33. Kokturk A, Kaya TI, Baz K, et al. Bullous erythema ab igne. Dermatol Online J. 2003;9:18.
  34. Brzezinski P, Ismail S, Chiriac A. Radiator-induced erythema ab igne in 8-year-old girl. Rev Chil Pediatr. 2014;85:239-240. doi:10.4067/S0370-41062014000200015
  35. Adams BB. Heated car seat-induced erythema ab igne. Arch Dermatol. 2012;148:265-266. doi:10.1001/archdermatol.2011.2207
  36. Helm TN, Spigel GT, Helm KF. Erythema ab igne caused by a car heater. Cutis. 1997;59:81-82.
  37. Gregory JF, Beute TC. Erythema ab igne. J Spec Oper Med. 2013;13:115-119. doi:10.55460/5AVH-NZHY
  38. Chua S, Chen Q, Lee HY. Erythema ab igne and dermal scarring caused by cupping and moxibustion treatment. J Dtsch Dermatol Ges. 2015;13:337-338. doi:10.1111/ddg.12581
  39. Chen JF, Liu YC, Chen YF, et al. Erythema ab igne after footbath with Chinese herbal remedies. J Chinese Med Assoc. 2011;74:51-53. doi:10.1016/j.jcma.2011.01.009
  40. Baltazar D, Brockman R, Simpson E. Kotatsu-induced erythema ab igne. An Bras Dermatol. 2019;94:253-254. doi:10.1590/abd1806-4841.20198792
  41. Baig M, Byrne F. Erythema ab igne and its relation to spinal pathology. Cureus. 2018;10:e2914. doi:10.7759/cureus.2914
  42. Aria AB, Chen L, Silapunt S. Erythema ab igne from heating pad use: a report of three clinical cases and a differential diagnosis. Cureus. 2018;10:e2635. doi:10.7759/cureus.2635
  43. Milchak M, Smucker J, Chung CG, et al. Erythema ab igne due to heating pad use: a case report and review of clinical presentation, prevention, and complications. Case Rep Med. 2016;1862480. doi:10.1155/2016/1862480
  44. Gmuca S, Yu J, Weiss PF, et al. Erythema ab igne in an adolescent with chronic pain: an alarming cutaneous eruption from heat exposure. Pediatr Emerg Care. 2020;36:e236-e238. doi:10.1097/PEC.0000000000001460
  45. Dizdarevic A, Karim OA, Bygum A. A reddish brown reticulated hyperpigmented erythema on the abdomen of a girl. Erythema ab igne, also known as toasted skin syndrome, caused by a heating pad onthe abdomen. Acta Derm Venereol. 2014;94:365-367. doi:10.2340/00015555-1722
  46. Chatterjee S. Erythema ab igne from prolonged use of a heating pad. Mayo Clin Proc. 2005;80:1500. doi:10.4065/80.11.1500
  47. Waldorf DS, Rast MF, Garofalo VJ. Heating-pad erythematous dermatitis “erythema ab igne.” JAMA. 1971;218:1704. doi:10.1001/jama.1971.03190240056023
  48. South AM, Crispin MK, Marqueling AL, et al. A hyperpigmented reticular rash in a patient on peritoneal dialysis. Perit Dial Int. 2016;36:677-700. doi:10.3747/pdi.2016.00042
  49. Ravindran R. Erythema ab igne in an individual with diabetes and gastroparesis. BMJ Case Rep. 2017;2017:bcr2014203856. doi:10.1136/bcr-2014-203856
  50. Dessinioti C, Katsambas A, Tzavela E, et al. Erythema ab igne in three girls with anorexia nervosa. Pediatr Dermatol. 2016;33:e149-e150. doi:10.1111/pde.12770
  51. Fischer J, Rein K, Erfurt-Berge C, et al. Three cases of erythema ab igne (EAI) in patients with eating disorders. Neuropsychiatr. 2010;24:141-143.
  52. Docx MKF, Simons A, Ramet J, et al. Erythema ab igne in an adolescent with anorexia nervosa. Int J Eat Disord. 2013;46:381-383. doi:10.1002/eat.22075
  53. Turan E, Cimen V, Haytoglu NSK, et al. A case of bullous erythema ab igne accompanied by anemia and subclinical hypothyroidism. Dermatol Online J. 2014;20:223366.
  54. Pavithran K. Erythema ab igne, schizophrenia and thermophilia. Indian J Dermatol Venereol Leprol. 1987;53:181-182.
  55. Dellavelle R, Gillum P. Erythema ab igne following heating/cooling blanket use in the intensive care unit. Cutis. 2000;66:136-138.
  56. Park SY, Kim SM, Yoon TJ. Erythema ab igne caused by weight loss heating pad. Korean J Dermatol. 2007;45:489-491.
  57. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98:75-81. doi:10.1016/j.jdermsci.2020.04.011
  58. Gisondi P, Plaserico S, Bordin C, et al. Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020;34:2499-2504. doi:10.1111/jdv.16774
  59. Manalo IF, Smith MK, Cheeley J, et al. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83:700. doi:10.1016/j.jaad.2020.04.018
  60. Zhao Q, Fang X, Pang Z, et al. COVID‐19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020;34:2505-2510. doi:10.1111/jdv.16778
  61. Akasaka T, Kon S. Two cases of squamous cell carcinoma arising from erythema ab igne. Nihon Hifuka Gakkai Zasshi. 1989;99:735-742.
  62. Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. Arch Dermatol. 1979;115:1226-1228.
  63. Wharton JB, Sheehan DJ, Lesher JL Jr. Squamous cell carcinoma in situ arising in the setting of erythema ab igne. J Drugs Dermatol. 2008;7:488-489.
  64. Wollina U, Helm C, Hansel G, et al. Two cases of erythema ab igne, one with a squamous cell carcinoma. G Ital Dermatol Venereol. 2007;142:415-418.
  65. Rudolph CM, Soyer HP, Wolf P, et al. Squamous cell carcinoma arising in erythema ab igne. Hautarzt. 2000;51:260-263. doi:10.1007/s001050051115
  66. Sigmon JR, Cantrell J, Teague D, et al. Poorly differentiated carcinoma arising in the setting of erythema ab igne. Am J Dermatopathol. 2013;35:676-678. doi:10.1097/DAD.0b013e3182871648
  67. Wharton J, Roffwarg D, Miller J, et al. Cutaneous marginal zone lymphoma arising in the setting of erythema ab igne. J Am Acad Dermatol. 2010;62:1080-1081. doi:10.1016/j.jaad.2009.08.005
  68. Jones CS, Tyring SK, Lee PC, et al. Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol. 1988;124:110-113.
  69. Kim HW, Kim EJ, Park HC, et al. Erythema ab igne successfully treated with low fluenced 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet laser. J Cosmet Laser Ther. 2014;16:147-148. doi:10.3109/14764172.2013.854623
  70. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;62:77-78.
  71. Gianfaldoni S, Gianfaldoni R, Tchernev G, et al. Erythema ab igne successfully treated with mesoglycan and bioflavonoids: a case-report. Open Access Maced J Med Sci. 2017;5:432-435. doi:10.3889/oamjms.2017.123
Article PDF
Author and Disclosure Information

Dr. Harview is from the Department of Internal Medicine, The University of Arizona College of Medicine, Phoenix. Dr. Krenitsky is from the Department of Dermatology, University of South Florida, Tampa.

The authors report no conflict of interest.

Correspondence: Christina L. Harview, MD (clharview@gmail.com).

Issue
Cutis - 111(4)
Publications
Topics
Page Number
E33-E38
Sections
Author and Disclosure Information

Dr. Harview is from the Department of Internal Medicine, The University of Arizona College of Medicine, Phoenix. Dr. Krenitsky is from the Department of Dermatology, University of South Florida, Tampa.

The authors report no conflict of interest.

Correspondence: Christina L. Harview, MD (clharview@gmail.com).

Author and Disclosure Information

Dr. Harview is from the Department of Internal Medicine, The University of Arizona College of Medicine, Phoenix. Dr. Krenitsky is from the Department of Dermatology, University of South Florida, Tampa.

The authors report no conflict of interest.

Correspondence: Christina L. Harview, MD (clharview@gmail.com).

Article PDF
Article PDF

Erythema ab igne (EAI)(also known as toasted skin syndrome) was first described in the British Journal of Dermatology in the 20th century, 1 though it was known by physicians long before. Reticular netlike skin changes were seen in association with patients who spent extended time directly next to a heat source. This association led to the name of this condition, which literally means “redness by fire.” Indeed, EAI induced by chronic heat exposure has been described across the world for centuries. For example, in the cold regions of northern China, people used to sleep on beds of hot bricks called kang to stay warm at night. The people of India’s Kashmir district carried pots of hot coals called kangri next to the skin under large woven shawls to stay warm. In the past, Irish women often spent much time by a turf- or peat-burning fire. Chronic heat exposure in these cases can lead not only to EAI but also to aggressive types of cancer, often with a latency of 30 years or more. 2

More recently, the invention of home central heating led to a stark decrease in the number of cases associated with combustion-based heat, with a transition to etiologies such as use of hot water bottles, electric blankets, and electric space heaters. Over time, technological advances led to ever-increasing potential causes for EAI, such as laptops or cell phones, car heaters and heated seats, heated blankets,3,4 infrared lamps for food, and even medical devices such as ultrasound-based heating products and convective temperature management systems for hospitalized patients. As technology evolves, so do the potential causes of EAI, requiring clinicians to diagnose and deduce the cause through a thorough social and medical history as well as a workup on the present illness with considerations for the anatomical location.5-7 Herein, we describe the etiology of EAI, diagnosis, and treatment options.

Erythema ab igne secondary to use of a space heater nightly for 6 months.
FIGURE 1. Erythema ab igne secondary to use of a space heater nightly for 6 months.

Clinical Characteristics

Erythema ab igne begins as mild, transient, and erythematous macules and patches in a reticular pattern that resolve minutes to hours after removal of the heat source. With weeks to months of continued or repeated application of the heat source, the affected area eventually becomes hyperpigmented where there once was erythema (Figures 1 and 2). Sometimes papules, bullae, telangiectasia, and hyperkeratosis also form. The rash usually is asymptomatic, though pain, pruritus, and dysesthesia have been reported.7 Dermoscopy of EAI in the hyperpigmented stage can reveal diffuse superficial dark pigmentation, telangiectasia, and mild whitish scaling.8 Although the pathogenesis has remained elusive over the years, lesions do seem to be mostly associated with cumulative exposure to heat rather than length of exposure.7

Biopsy-proven erythema ab igne in a patient with darker skin.
FIGURE 2. Biopsy-proven erythema ab igne in a patient with darker skin.

Etiology of EAI

Anatomic Location—The affected site depends on the source of heat (Table). Classic examples of this condition include a patient with EAI presenting on the anterior thighs after working in front of a hot oven or a patient with chronic back pain presenting with lower-back EAI secondary to frequent use of a hot water bottle or heating pad.7 With evolving technology over the last few decades, new etiologies have become more common—teenagers are presenting with anterior thigh EAI secondary to frequent laptop use2-29; patients are holding warm cell phones in their pant pockets, leading to unilateral geometric EAI on the anterior thigh (front pocket) or buttock (back pocket)30; plug-in radiators under computer desks are causing EAI on the lower legs31-34; and automobile seat heaters have been shown to cause EAI on the posterior legs.5,35-37 Clinicians should consider anatomic location a critical clue for etiology.

Etiologic Considerations and Possible Comorbidities Based on Anatomic Location of Erythema Ab Igne

Social History—There are rarer and more highly specific causes of EAI than simple heat exposure that can be parsed from a patient’s social history. Occupational exposure has been documented, such as bakers with exposure to ovens, foundry workers with exposure to heated metals, or fast-food workers with chronic exposure to infrared food lamps.6,7 There also are cultural practices that can cause EAI. For example, the practice of cupping with moxibustion was shown to create a specific pattern in the shape of the cultural tool used.38 When footbaths with Chinese herbal remedies are performed frequently with high heat, they can lead to EAI on the feet with a linear border at the ankles. There also have been reports of kotatsu (heated tables in Japan) leading to lower-body EAI.39,40 These cultural practices also are more common in patients with darker skin types, which can lead to hyperpigmentation that is difficult to treat, making early diagnosis important.7

Medical History—Case reports have shown EAI caused by patients attempting to use heat-based methods for pain relief of an underlying serious disease such as cancer, bowel pathology (abdominal EAI), spinal disc prolapse (midline back EAI),41 sickle cell anemia, and renal pathology (posterior upper flank EAI).6,7,40-49 Patients with hypothyroidism or anorexia have been noted to have generalized EAI sparing the face secondary to repeated and extended hot baths or showers.50-53 One patient with schizophrenia was shown to have associated thermophilia due to a delusion that led the patient to soak in hot baths for long periods of time, leading to EAI.54 Finally, all physicians should be aware of iatrogenic causes of EAI, such as use of warming devices, ultrasound-based warming techniques, and laser therapy for lipolysis. Inquire about the patient’s surgical history or intensive care unit stays as well as alternative medicine or chiropractic visits. Obtaining a history of medical procedures can be enlightening when an etiology is not immediately clear.7,55,56

Diagnosis

Erythema ab igne is a clinical diagnosis based on recognizable cutaneous findings and a clear history of moderate heat exposure. However, when a clinical diagnosis of EAI is not certain (eg, when unable to obtain a clear history from the patient) or when malignant transformation is suspected, a biopsy can be performed. Pathologically, hematoxylin and eosin staining of EAI classically reveals dilated small vascular channels in the superficial dermis, hence a clinically reticular rash; interface dermatitis clinically manifesting as erythema; and pigment incontinence with melanin-laden macrophages consistent with clinical hyperpigmentation. Finally, for unclear reasons, increased numbers of elastic fibers classically are seen in biopsies of EAI.7

 

 

Differential Diagnosis

The differential diagnosis for a reticular patch includes livedo reticularis (Figure 3), which usually manifests as a more generalized rash in patients with chronic disease or coagulopathy such as systemic lupus erythematosus, cryoglobulinemia, or Raynaud phenomenon. When differentiating EAI from livedo reticularis or cutis marmorata, consider that both alternative diagnoses are more vascular appearing and are associated with cold exposure rather than heat exposure. In cases that are less reticular, livedo racemosa can be considered in the differential diagnosis. Finally, poikiloderma of Civatte can be reticular, particularly on dermoscopy, but the distribution on the neck with submental sparing should help to distinguish it from EAI unless a heat source around the neck is identified while taking the patient’s history.7

Livedo reticularis in a patient with chronic autoimmune disease.
FIGURE 3. Livedo reticularis in a patient with chronic autoimmune disease.

In babies, a reticular generalized rash is most likely to be cutis marmorata (Figure 4), which is a physiologic response to cold exposure that resolves with rewarming of the skin. A more serious condition—cutis marmorata telangiectatica congenita (Figure 5)—usually is present at birth, most frequently involves a single extremity, and notably does not resolve with rewarming. This is an important differential for EAI in children because it can be associated with vascular and neurologic anomalies as well as limb asymmetry. Finally, port-wine stains can sometimes be reticular in appearance and can mimic the early erythematous stages of EAI. However, unlike the erythematous stage of EAI, the port-wine stains will be present at birth.7

Cutis marmorata in a 1-month-old infant.
FIGURE 4. Cutis marmorata in a 1-month-old infant.

Emerging in 2020, an important differential diagnosis to consider is a cutaneous manifestation of COVID-19 infection. An erythematous, reticular, chilblainlike or transient livedo reticularis–like rash has been described as a cutaneous manifestation of COVID-19. Although the pathophysiology is still being elucidated, it is suspected that this is caused by a major vaso-occlusive crisis secondary to COVID-19–induced thrombotic vasculopathy. Interestingly, the majority of patients with this COVID-related exanthem also displayed symptoms of COVID-19 (eg, fever, cough) at the time of presentation,57-60 but there also have been cases in patients who were asymptomatic or mildly symptomatic.60

Cutis marmorata telangiectatica congenita in a 3-month-old infant.
FIGURE 5. Cutis marmorata telangiectatica congenita in a 3-month-old infant.

In some cases, EAI is an indication to screen for an underlying disease. For example, uncontrolled pain is an opportunity to improve interventions such as modifying the patient’s pain-control regimen, placing a palliative care pain consultation, or checking if the patient has had age-appropriate screenings for malignancy. New focal pain in a patient with a prior diagnosis of cancer may be a sign of a new metastasis. A thermophilic patient leaves opportunity to assess for underlying medical causes such as thyroid abnormalities or social/psychological issues. Geriatric patients who are diagnosed with EAI may need to be assessed for dementia or home safety issues. Patients with a history of diabetes mellitus can unknowingly develop EAI on the lower extremities, which may signal a need to assess the patient for peripheral neuropathy. Patients with gastroparesis secondary to diabetes also may develop EAI on the abdomen secondary to heating pad use for discomfort. These examples are a reminder to consider possible secondary comorbidities in all diagnoses of EAI.7 

Prognosis

Although the prognosis of EAI is excellent if caught early, failure to diagnose this condition can lead to permanent discoloration of the skin and even malignancy.6 A rare sequela includes squamous cell carcinoma, most commonly seen in chronic cases of the lower leg, which is likely related to chronic inflammation of the skin.61-65 Rare cases of poorly differentiated carcinoma,66 cutaneous marginal zone lymphoma,67 and Merkel cell carcinoma68 have been reported. Patients diagnosed with EAI should receive normal periodic surveillance of the skin based on their medical history, though the physician should have an increased suspicion and plan for biopsy of any nodules or ulcerations found on the skin of the affected area.7

Treatments

Once the diagnosis of EAI is made, treatment starts with removal of the heat source causing the rash. Because the rash usually is asymptomatic, further treatment typically is not required. The discoloration can resolve over months or years, but permanent hyperpigmentation is not uncommon. If hyperpigmentation persists despite removal of the heat source and the patient desires further treatment for discoloration, there are few treatment options, none of which are approved by the US Food and Drug Administration for this condition.7 There is some evidence for the use of Nd:YAG lasers to reduce hyperpigmentation in EAI.69 There have been some reports of treatment using topical hydroquinone and topical tretinoin in an attempt to lighten the skin. If associated hyperkeratosis or other epithelial atypia is present, the use of 5-fluorouracil may show some improvement.70 One case report has been published of successful treatment with systemic mesoglycan and topical bioflavonoids.71 It also is conceivable that medications used to treat postinflammatory hyperpigmentation may be helpful in this condition (eg, kojic acid, arbutin, mild topical steroids, azelaic acid). Patients with darker skin may experience permanent discoloration and may not be good candidates for alternative treatments such as laser therapy due to the risk for inducible hyperpigmentation.7

Conclusion

No matter the etiology, EAI usually is a benign skin condition that is treated by removal of the causative heat source. Once a diagnosis is made, the clinician must work with the patient to determine the etiology. Care must be taken to ensure that there are no underlying signs, such as chronic pain or psychiatric illness, that could point to associated conditions. Rarely, sequalae such as cancers have been documented in areas of chronic EAI. Once the heat source is identified and removed, any remaining hyperpigmentation usually will self-resolve over months to years, though this may take longer in patients with darker skin types. If more aggressive treatment is preferred by the patient, laser therapy, topical medications, and oral over-the-counter vitamins have been tried with minimal responses. 

Erythema ab igne (EAI)(also known as toasted skin syndrome) was first described in the British Journal of Dermatology in the 20th century, 1 though it was known by physicians long before. Reticular netlike skin changes were seen in association with patients who spent extended time directly next to a heat source. This association led to the name of this condition, which literally means “redness by fire.” Indeed, EAI induced by chronic heat exposure has been described across the world for centuries. For example, in the cold regions of northern China, people used to sleep on beds of hot bricks called kang to stay warm at night. The people of India’s Kashmir district carried pots of hot coals called kangri next to the skin under large woven shawls to stay warm. In the past, Irish women often spent much time by a turf- or peat-burning fire. Chronic heat exposure in these cases can lead not only to EAI but also to aggressive types of cancer, often with a latency of 30 years or more. 2

More recently, the invention of home central heating led to a stark decrease in the number of cases associated with combustion-based heat, with a transition to etiologies such as use of hot water bottles, electric blankets, and electric space heaters. Over time, technological advances led to ever-increasing potential causes for EAI, such as laptops or cell phones, car heaters and heated seats, heated blankets,3,4 infrared lamps for food, and even medical devices such as ultrasound-based heating products and convective temperature management systems for hospitalized patients. As technology evolves, so do the potential causes of EAI, requiring clinicians to diagnose and deduce the cause through a thorough social and medical history as well as a workup on the present illness with considerations for the anatomical location.5-7 Herein, we describe the etiology of EAI, diagnosis, and treatment options.

Erythema ab igne secondary to use of a space heater nightly for 6 months.
FIGURE 1. Erythema ab igne secondary to use of a space heater nightly for 6 months.

Clinical Characteristics

Erythema ab igne begins as mild, transient, and erythematous macules and patches in a reticular pattern that resolve minutes to hours after removal of the heat source. With weeks to months of continued or repeated application of the heat source, the affected area eventually becomes hyperpigmented where there once was erythema (Figures 1 and 2). Sometimes papules, bullae, telangiectasia, and hyperkeratosis also form. The rash usually is asymptomatic, though pain, pruritus, and dysesthesia have been reported.7 Dermoscopy of EAI in the hyperpigmented stage can reveal diffuse superficial dark pigmentation, telangiectasia, and mild whitish scaling.8 Although the pathogenesis has remained elusive over the years, lesions do seem to be mostly associated with cumulative exposure to heat rather than length of exposure.7

Biopsy-proven erythema ab igne in a patient with darker skin.
FIGURE 2. Biopsy-proven erythema ab igne in a patient with darker skin.

Etiology of EAI

Anatomic Location—The affected site depends on the source of heat (Table). Classic examples of this condition include a patient with EAI presenting on the anterior thighs after working in front of a hot oven or a patient with chronic back pain presenting with lower-back EAI secondary to frequent use of a hot water bottle or heating pad.7 With evolving technology over the last few decades, new etiologies have become more common—teenagers are presenting with anterior thigh EAI secondary to frequent laptop use2-29; patients are holding warm cell phones in their pant pockets, leading to unilateral geometric EAI on the anterior thigh (front pocket) or buttock (back pocket)30; plug-in radiators under computer desks are causing EAI on the lower legs31-34; and automobile seat heaters have been shown to cause EAI on the posterior legs.5,35-37 Clinicians should consider anatomic location a critical clue for etiology.

Etiologic Considerations and Possible Comorbidities Based on Anatomic Location of Erythema Ab Igne

Social History—There are rarer and more highly specific causes of EAI than simple heat exposure that can be parsed from a patient’s social history. Occupational exposure has been documented, such as bakers with exposure to ovens, foundry workers with exposure to heated metals, or fast-food workers with chronic exposure to infrared food lamps.6,7 There also are cultural practices that can cause EAI. For example, the practice of cupping with moxibustion was shown to create a specific pattern in the shape of the cultural tool used.38 When footbaths with Chinese herbal remedies are performed frequently with high heat, they can lead to EAI on the feet with a linear border at the ankles. There also have been reports of kotatsu (heated tables in Japan) leading to lower-body EAI.39,40 These cultural practices also are more common in patients with darker skin types, which can lead to hyperpigmentation that is difficult to treat, making early diagnosis important.7

Medical History—Case reports have shown EAI caused by patients attempting to use heat-based methods for pain relief of an underlying serious disease such as cancer, bowel pathology (abdominal EAI), spinal disc prolapse (midline back EAI),41 sickle cell anemia, and renal pathology (posterior upper flank EAI).6,7,40-49 Patients with hypothyroidism or anorexia have been noted to have generalized EAI sparing the face secondary to repeated and extended hot baths or showers.50-53 One patient with schizophrenia was shown to have associated thermophilia due to a delusion that led the patient to soak in hot baths for long periods of time, leading to EAI.54 Finally, all physicians should be aware of iatrogenic causes of EAI, such as use of warming devices, ultrasound-based warming techniques, and laser therapy for lipolysis. Inquire about the patient’s surgical history or intensive care unit stays as well as alternative medicine or chiropractic visits. Obtaining a history of medical procedures can be enlightening when an etiology is not immediately clear.7,55,56

Diagnosis

Erythema ab igne is a clinical diagnosis based on recognizable cutaneous findings and a clear history of moderate heat exposure. However, when a clinical diagnosis of EAI is not certain (eg, when unable to obtain a clear history from the patient) or when malignant transformation is suspected, a biopsy can be performed. Pathologically, hematoxylin and eosin staining of EAI classically reveals dilated small vascular channels in the superficial dermis, hence a clinically reticular rash; interface dermatitis clinically manifesting as erythema; and pigment incontinence with melanin-laden macrophages consistent with clinical hyperpigmentation. Finally, for unclear reasons, increased numbers of elastic fibers classically are seen in biopsies of EAI.7

 

 

Differential Diagnosis

The differential diagnosis for a reticular patch includes livedo reticularis (Figure 3), which usually manifests as a more generalized rash in patients with chronic disease or coagulopathy such as systemic lupus erythematosus, cryoglobulinemia, or Raynaud phenomenon. When differentiating EAI from livedo reticularis or cutis marmorata, consider that both alternative diagnoses are more vascular appearing and are associated with cold exposure rather than heat exposure. In cases that are less reticular, livedo racemosa can be considered in the differential diagnosis. Finally, poikiloderma of Civatte can be reticular, particularly on dermoscopy, but the distribution on the neck with submental sparing should help to distinguish it from EAI unless a heat source around the neck is identified while taking the patient’s history.7

Livedo reticularis in a patient with chronic autoimmune disease.
FIGURE 3. Livedo reticularis in a patient with chronic autoimmune disease.

In babies, a reticular generalized rash is most likely to be cutis marmorata (Figure 4), which is a physiologic response to cold exposure that resolves with rewarming of the skin. A more serious condition—cutis marmorata telangiectatica congenita (Figure 5)—usually is present at birth, most frequently involves a single extremity, and notably does not resolve with rewarming. This is an important differential for EAI in children because it can be associated with vascular and neurologic anomalies as well as limb asymmetry. Finally, port-wine stains can sometimes be reticular in appearance and can mimic the early erythematous stages of EAI. However, unlike the erythematous stage of EAI, the port-wine stains will be present at birth.7

Cutis marmorata in a 1-month-old infant.
FIGURE 4. Cutis marmorata in a 1-month-old infant.

Emerging in 2020, an important differential diagnosis to consider is a cutaneous manifestation of COVID-19 infection. An erythematous, reticular, chilblainlike or transient livedo reticularis–like rash has been described as a cutaneous manifestation of COVID-19. Although the pathophysiology is still being elucidated, it is suspected that this is caused by a major vaso-occlusive crisis secondary to COVID-19–induced thrombotic vasculopathy. Interestingly, the majority of patients with this COVID-related exanthem also displayed symptoms of COVID-19 (eg, fever, cough) at the time of presentation,57-60 but there also have been cases in patients who were asymptomatic or mildly symptomatic.60

Cutis marmorata telangiectatica congenita in a 3-month-old infant.
FIGURE 5. Cutis marmorata telangiectatica congenita in a 3-month-old infant.

In some cases, EAI is an indication to screen for an underlying disease. For example, uncontrolled pain is an opportunity to improve interventions such as modifying the patient’s pain-control regimen, placing a palliative care pain consultation, or checking if the patient has had age-appropriate screenings for malignancy. New focal pain in a patient with a prior diagnosis of cancer may be a sign of a new metastasis. A thermophilic patient leaves opportunity to assess for underlying medical causes such as thyroid abnormalities or social/psychological issues. Geriatric patients who are diagnosed with EAI may need to be assessed for dementia or home safety issues. Patients with a history of diabetes mellitus can unknowingly develop EAI on the lower extremities, which may signal a need to assess the patient for peripheral neuropathy. Patients with gastroparesis secondary to diabetes also may develop EAI on the abdomen secondary to heating pad use for discomfort. These examples are a reminder to consider possible secondary comorbidities in all diagnoses of EAI.7 

Prognosis

Although the prognosis of EAI is excellent if caught early, failure to diagnose this condition can lead to permanent discoloration of the skin and even malignancy.6 A rare sequela includes squamous cell carcinoma, most commonly seen in chronic cases of the lower leg, which is likely related to chronic inflammation of the skin.61-65 Rare cases of poorly differentiated carcinoma,66 cutaneous marginal zone lymphoma,67 and Merkel cell carcinoma68 have been reported. Patients diagnosed with EAI should receive normal periodic surveillance of the skin based on their medical history, though the physician should have an increased suspicion and plan for biopsy of any nodules or ulcerations found on the skin of the affected area.7

Treatments

Once the diagnosis of EAI is made, treatment starts with removal of the heat source causing the rash. Because the rash usually is asymptomatic, further treatment typically is not required. The discoloration can resolve over months or years, but permanent hyperpigmentation is not uncommon. If hyperpigmentation persists despite removal of the heat source and the patient desires further treatment for discoloration, there are few treatment options, none of which are approved by the US Food and Drug Administration for this condition.7 There is some evidence for the use of Nd:YAG lasers to reduce hyperpigmentation in EAI.69 There have been some reports of treatment using topical hydroquinone and topical tretinoin in an attempt to lighten the skin. If associated hyperkeratosis or other epithelial atypia is present, the use of 5-fluorouracil may show some improvement.70 One case report has been published of successful treatment with systemic mesoglycan and topical bioflavonoids.71 It also is conceivable that medications used to treat postinflammatory hyperpigmentation may be helpful in this condition (eg, kojic acid, arbutin, mild topical steroids, azelaic acid). Patients with darker skin may experience permanent discoloration and may not be good candidates for alternative treatments such as laser therapy due to the risk for inducible hyperpigmentation.7

Conclusion

No matter the etiology, EAI usually is a benign skin condition that is treated by removal of the causative heat source. Once a diagnosis is made, the clinician must work with the patient to determine the etiology. Care must be taken to ensure that there are no underlying signs, such as chronic pain or psychiatric illness, that could point to associated conditions. Rarely, sequalae such as cancers have been documented in areas of chronic EAI. Once the heat source is identified and removed, any remaining hyperpigmentation usually will self-resolve over months to years, though this may take longer in patients with darker skin types. If more aggressive treatment is preferred by the patient, laser therapy, topical medications, and oral over-the-counter vitamins have been tried with minimal responses. 

References
  1. Perry. Case of erythema ab igne. Br J Dermatol. 1900;xxiii:375.
  2. Bose S, Ortonee JP. Diseases affected by heat. In: Parish LC, Millikan LE, Amer M, et al. Global Dermatology Diagnosis and Management According to Geography, Climate, and Culture. Springer-Varlag; 1994:83-92.
  3. Leal-Lobato MM, Blasco-Morente G. Electric blanket induced erythema ab igne [in Spanish]. Semergen. 2015;41:456-457. doi:10.1016/j.semerg.2014.12.008
  4. Huynh N, Sarma D, Huerter C. Erythema ab igne: a case report and review of the literature. Cutis. 2011;88:290-292.
  5. Kesty K, Feldman SR. Erythema ab igne: evolving technology, evolving presentation. Dermatol Online J. 2014;20. doi:10.5070/D32011024689
  6. Miller K, Hunt R, Chu J, et al. Erythema ab igne. Dermatol Online J. 2011;17:28.
  7. Smith ML. Environmental and sports-related skin diseases. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Elsevier; 2018:1569-1594.
  8. Errichetti E, Stinco G. Dermoscopy in general dermatology: a practical overview. Dermatol Ther (Heidelb). 2016;6:471-507. doi:10.1007/s13555-016-0141-6
  9. Guarneri C, Tchernev G, Wollina U, et al. Erythema ab igne caused by laptop computer. Open Access Maced J Med Sci. 2017;5:490-492. doi:10.3889/oamjms.2017.137
  10. Arnold AW, Itin PH. Laptop computer-induced erythema ab igne in a child and review of the literature. Pediatrics. 2010;126:E1227-E1230. doi:10.1542/peds.2010-1390
  11. Dickman J, Kessler S. Unilateral reticulated patch localized to the anterior thigh. JAAD Case Rep. 2018;4:746-748. doi:10.1016/j.jdcr.2018.06.007
  12. Boffa MJ. Laptop computer-induced erythema ab igne on the left breast. Cutis. 2011;87:175-176.
  13. Li K, Barankin B. Cutaneous manifestations of modern technology use. J Cutan Med Surg. 2011;15:347-353. doi:10.2310/7750.2011.10053
  14. Riahi RR, Cohen PR. Laptop-induced erythema ab igne: report and review of literature. Dermatol Online J. 2012;18:5.
  15. Andersen F. Laptop-thighs--laptop-induced erythema ab igne [in Danish]. Ugeskr Laeger. 2010;172:635.
  16. Jagtman BA. Erythema ab igne due to a laptop computer. Contact Dermatitis. 2004;50:105. doi:10.1111/j.0105-1873.2004.0295g.x
  17. Olechowska M, Kisiel K, Ruszkowska L, et al. Erythema ab igne (EAI) induced by a laptop computer: report of two cases. J Dtsch Dermatol Ges. doi:10.1111/j.1610-0387.2014.12387
  18. Nayak SUK, Shenoi SD, Prabhu S. Laptop induced erythema ab igne. Indian J Dermatol. 2012;57:131-132. doi:10.4103/0019-5154.94284
  19. Salvio AG, Nunes AJ, Angarita DPR. Laptop computer induced erythema ab igne: a new presentation of an old disease. An Bras Dermatol. 2016;91:79-80. doi:10.1590/abd1806-4841.20165139
  20. Schummer C, Tittelbach J, Elsner P. Right-sided laptop dermatitis [in German]. Dtsch Med Wochenschr. 2015;140:1376-1377. doi:10.1055/s-0041-103615
  21. Manoharan D. Erythema ab igne: usual site, unusual cause. J Pharm Bioallied Sci. 2015;7(suppl 1):S74-S75. doi:10.4103/0975-7406.155811
  22. Giraldi S, Diettrich F, Abbage KT, et al. Erythema ab igne induced by a laptop computer in an adolescent. An Bras Dermatol. 2011;86:128-130. doi:10.1590/S0365-05962011000100018
  23. Secher LLS, Vind-Kezunovic D, Zachariae COC. Side-effects to the use of laptop computers: erythema ab igne. Dermatol Reports. 2010;31:E11. doi:10.4081/dr.2010.e11
  24. Botten D, Langley RGB, Webb A. Academic branding: erythema ab igne and use of laptop computers. CMAJ. 2010;182:E857. doi:10.1503/cmaj.091868
  25. Bilic M, Adams BB. Erythema ab igne induced by a laptop computer. J Am Acad Dermatol. 2004;50:973-974. doi:10.1016/j.jaad.2003.08.007
  26. Fu LW, Vender R. Erythema ab igne caused by laptop computer gaming - a case report. Int J Dermatol. 2012;51:716-717. doi:10.1111/j.1365-4632.2011.05033.x
  27. Levinbook WS, Mallett J, Grant-Kels JM. Laptop computer-associated erythema ab igne. Cutis. 2007;80:319-320.
  28. Mohr MR, Scott KA, Pariser RM, et al. Laptop computer-induced erythema ab igne: a case report. Cutis. 2007;79:59-60.
  29. Cantor AS, Bartling SJ. Laptop computer-induced hyperpigmentation. Dermatol Online J. 2018;24:13030/qt6k37r9wm.
  30. Kaptanog˘lu AF, Mullaaziz D. Erythema ab igne in the palmar area induced by smart phone: case report. Turkiye Klin J Med Sci. 2015;35:284-286. doi:10.5336/medsci.2015-46976
  31. Redding KS, Watts AN, Lee J, et al. Space heater-induced bullous erythema ab igne. Cutis. 2017;100:E9-E10.
  32. Goorland J, Edens MA, Baudoin TD. An emergency department presentation of erythema ab igne caused by repeated heater exposure. J La State Med Soc. 2016;168:33-34.
  33. Kokturk A, Kaya TI, Baz K, et al. Bullous erythema ab igne. Dermatol Online J. 2003;9:18.
  34. Brzezinski P, Ismail S, Chiriac A. Radiator-induced erythema ab igne in 8-year-old girl. Rev Chil Pediatr. 2014;85:239-240. doi:10.4067/S0370-41062014000200015
  35. Adams BB. Heated car seat-induced erythema ab igne. Arch Dermatol. 2012;148:265-266. doi:10.1001/archdermatol.2011.2207
  36. Helm TN, Spigel GT, Helm KF. Erythema ab igne caused by a car heater. Cutis. 1997;59:81-82.
  37. Gregory JF, Beute TC. Erythema ab igne. J Spec Oper Med. 2013;13:115-119. doi:10.55460/5AVH-NZHY
  38. Chua S, Chen Q, Lee HY. Erythema ab igne and dermal scarring caused by cupping and moxibustion treatment. J Dtsch Dermatol Ges. 2015;13:337-338. doi:10.1111/ddg.12581
  39. Chen JF, Liu YC, Chen YF, et al. Erythema ab igne after footbath with Chinese herbal remedies. J Chinese Med Assoc. 2011;74:51-53. doi:10.1016/j.jcma.2011.01.009
  40. Baltazar D, Brockman R, Simpson E. Kotatsu-induced erythema ab igne. An Bras Dermatol. 2019;94:253-254. doi:10.1590/abd1806-4841.20198792
  41. Baig M, Byrne F. Erythema ab igne and its relation to spinal pathology. Cureus. 2018;10:e2914. doi:10.7759/cureus.2914
  42. Aria AB, Chen L, Silapunt S. Erythema ab igne from heating pad use: a report of three clinical cases and a differential diagnosis. Cureus. 2018;10:e2635. doi:10.7759/cureus.2635
  43. Milchak M, Smucker J, Chung CG, et al. Erythema ab igne due to heating pad use: a case report and review of clinical presentation, prevention, and complications. Case Rep Med. 2016;1862480. doi:10.1155/2016/1862480
  44. Gmuca S, Yu J, Weiss PF, et al. Erythema ab igne in an adolescent with chronic pain: an alarming cutaneous eruption from heat exposure. Pediatr Emerg Care. 2020;36:e236-e238. doi:10.1097/PEC.0000000000001460
  45. Dizdarevic A, Karim OA, Bygum A. A reddish brown reticulated hyperpigmented erythema on the abdomen of a girl. Erythema ab igne, also known as toasted skin syndrome, caused by a heating pad onthe abdomen. Acta Derm Venereol. 2014;94:365-367. doi:10.2340/00015555-1722
  46. Chatterjee S. Erythema ab igne from prolonged use of a heating pad. Mayo Clin Proc. 2005;80:1500. doi:10.4065/80.11.1500
  47. Waldorf DS, Rast MF, Garofalo VJ. Heating-pad erythematous dermatitis “erythema ab igne.” JAMA. 1971;218:1704. doi:10.1001/jama.1971.03190240056023
  48. South AM, Crispin MK, Marqueling AL, et al. A hyperpigmented reticular rash in a patient on peritoneal dialysis. Perit Dial Int. 2016;36:677-700. doi:10.3747/pdi.2016.00042
  49. Ravindran R. Erythema ab igne in an individual with diabetes and gastroparesis. BMJ Case Rep. 2017;2017:bcr2014203856. doi:10.1136/bcr-2014-203856
  50. Dessinioti C, Katsambas A, Tzavela E, et al. Erythema ab igne in three girls with anorexia nervosa. Pediatr Dermatol. 2016;33:e149-e150. doi:10.1111/pde.12770
  51. Fischer J, Rein K, Erfurt-Berge C, et al. Three cases of erythema ab igne (EAI) in patients with eating disorders. Neuropsychiatr. 2010;24:141-143.
  52. Docx MKF, Simons A, Ramet J, et al. Erythema ab igne in an adolescent with anorexia nervosa. Int J Eat Disord. 2013;46:381-383. doi:10.1002/eat.22075
  53. Turan E, Cimen V, Haytoglu NSK, et al. A case of bullous erythema ab igne accompanied by anemia and subclinical hypothyroidism. Dermatol Online J. 2014;20:223366.
  54. Pavithran K. Erythema ab igne, schizophrenia and thermophilia. Indian J Dermatol Venereol Leprol. 1987;53:181-182.
  55. Dellavelle R, Gillum P. Erythema ab igne following heating/cooling blanket use in the intensive care unit. Cutis. 2000;66:136-138.
  56. Park SY, Kim SM, Yoon TJ. Erythema ab igne caused by weight loss heating pad. Korean J Dermatol. 2007;45:489-491.
  57. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98:75-81. doi:10.1016/j.jdermsci.2020.04.011
  58. Gisondi P, Plaserico S, Bordin C, et al. Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020;34:2499-2504. doi:10.1111/jdv.16774
  59. Manalo IF, Smith MK, Cheeley J, et al. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83:700. doi:10.1016/j.jaad.2020.04.018
  60. Zhao Q, Fang X, Pang Z, et al. COVID‐19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020;34:2505-2510. doi:10.1111/jdv.16778
  61. Akasaka T, Kon S. Two cases of squamous cell carcinoma arising from erythema ab igne. Nihon Hifuka Gakkai Zasshi. 1989;99:735-742.
  62. Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. Arch Dermatol. 1979;115:1226-1228.
  63. Wharton JB, Sheehan DJ, Lesher JL Jr. Squamous cell carcinoma in situ arising in the setting of erythema ab igne. J Drugs Dermatol. 2008;7:488-489.
  64. Wollina U, Helm C, Hansel G, et al. Two cases of erythema ab igne, one with a squamous cell carcinoma. G Ital Dermatol Venereol. 2007;142:415-418.
  65. Rudolph CM, Soyer HP, Wolf P, et al. Squamous cell carcinoma arising in erythema ab igne. Hautarzt. 2000;51:260-263. doi:10.1007/s001050051115
  66. Sigmon JR, Cantrell J, Teague D, et al. Poorly differentiated carcinoma arising in the setting of erythema ab igne. Am J Dermatopathol. 2013;35:676-678. doi:10.1097/DAD.0b013e3182871648
  67. Wharton J, Roffwarg D, Miller J, et al. Cutaneous marginal zone lymphoma arising in the setting of erythema ab igne. J Am Acad Dermatol. 2010;62:1080-1081. doi:10.1016/j.jaad.2009.08.005
  68. Jones CS, Tyring SK, Lee PC, et al. Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol. 1988;124:110-113.
  69. Kim HW, Kim EJ, Park HC, et al. Erythema ab igne successfully treated with low fluenced 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet laser. J Cosmet Laser Ther. 2014;16:147-148. doi:10.3109/14764172.2013.854623
  70. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;62:77-78.
  71. Gianfaldoni S, Gianfaldoni R, Tchernev G, et al. Erythema ab igne successfully treated with mesoglycan and bioflavonoids: a case-report. Open Access Maced J Med Sci. 2017;5:432-435. doi:10.3889/oamjms.2017.123
References
  1. Perry. Case of erythema ab igne. Br J Dermatol. 1900;xxiii:375.
  2. Bose S, Ortonee JP. Diseases affected by heat. In: Parish LC, Millikan LE, Amer M, et al. Global Dermatology Diagnosis and Management According to Geography, Climate, and Culture. Springer-Varlag; 1994:83-92.
  3. Leal-Lobato MM, Blasco-Morente G. Electric blanket induced erythema ab igne [in Spanish]. Semergen. 2015;41:456-457. doi:10.1016/j.semerg.2014.12.008
  4. Huynh N, Sarma D, Huerter C. Erythema ab igne: a case report and review of the literature. Cutis. 2011;88:290-292.
  5. Kesty K, Feldman SR. Erythema ab igne: evolving technology, evolving presentation. Dermatol Online J. 2014;20. doi:10.5070/D32011024689
  6. Miller K, Hunt R, Chu J, et al. Erythema ab igne. Dermatol Online J. 2011;17:28.
  7. Smith ML. Environmental and sports-related skin diseases. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed. Elsevier; 2018:1569-1594.
  8. Errichetti E, Stinco G. Dermoscopy in general dermatology: a practical overview. Dermatol Ther (Heidelb). 2016;6:471-507. doi:10.1007/s13555-016-0141-6
  9. Guarneri C, Tchernev G, Wollina U, et al. Erythema ab igne caused by laptop computer. Open Access Maced J Med Sci. 2017;5:490-492. doi:10.3889/oamjms.2017.137
  10. Arnold AW, Itin PH. Laptop computer-induced erythema ab igne in a child and review of the literature. Pediatrics. 2010;126:E1227-E1230. doi:10.1542/peds.2010-1390
  11. Dickman J, Kessler S. Unilateral reticulated patch localized to the anterior thigh. JAAD Case Rep. 2018;4:746-748. doi:10.1016/j.jdcr.2018.06.007
  12. Boffa MJ. Laptop computer-induced erythema ab igne on the left breast. Cutis. 2011;87:175-176.
  13. Li K, Barankin B. Cutaneous manifestations of modern technology use. J Cutan Med Surg. 2011;15:347-353. doi:10.2310/7750.2011.10053
  14. Riahi RR, Cohen PR. Laptop-induced erythema ab igne: report and review of literature. Dermatol Online J. 2012;18:5.
  15. Andersen F. Laptop-thighs--laptop-induced erythema ab igne [in Danish]. Ugeskr Laeger. 2010;172:635.
  16. Jagtman BA. Erythema ab igne due to a laptop computer. Contact Dermatitis. 2004;50:105. doi:10.1111/j.0105-1873.2004.0295g.x
  17. Olechowska M, Kisiel K, Ruszkowska L, et al. Erythema ab igne (EAI) induced by a laptop computer: report of two cases. J Dtsch Dermatol Ges. doi:10.1111/j.1610-0387.2014.12387
  18. Nayak SUK, Shenoi SD, Prabhu S. Laptop induced erythema ab igne. Indian J Dermatol. 2012;57:131-132. doi:10.4103/0019-5154.94284
  19. Salvio AG, Nunes AJ, Angarita DPR. Laptop computer induced erythema ab igne: a new presentation of an old disease. An Bras Dermatol. 2016;91:79-80. doi:10.1590/abd1806-4841.20165139
  20. Schummer C, Tittelbach J, Elsner P. Right-sided laptop dermatitis [in German]. Dtsch Med Wochenschr. 2015;140:1376-1377. doi:10.1055/s-0041-103615
  21. Manoharan D. Erythema ab igne: usual site, unusual cause. J Pharm Bioallied Sci. 2015;7(suppl 1):S74-S75. doi:10.4103/0975-7406.155811
  22. Giraldi S, Diettrich F, Abbage KT, et al. Erythema ab igne induced by a laptop computer in an adolescent. An Bras Dermatol. 2011;86:128-130. doi:10.1590/S0365-05962011000100018
  23. Secher LLS, Vind-Kezunovic D, Zachariae COC. Side-effects to the use of laptop computers: erythema ab igne. Dermatol Reports. 2010;31:E11. doi:10.4081/dr.2010.e11
  24. Botten D, Langley RGB, Webb A. Academic branding: erythema ab igne and use of laptop computers. CMAJ. 2010;182:E857. doi:10.1503/cmaj.091868
  25. Bilic M, Adams BB. Erythema ab igne induced by a laptop computer. J Am Acad Dermatol. 2004;50:973-974. doi:10.1016/j.jaad.2003.08.007
  26. Fu LW, Vender R. Erythema ab igne caused by laptop computer gaming - a case report. Int J Dermatol. 2012;51:716-717. doi:10.1111/j.1365-4632.2011.05033.x
  27. Levinbook WS, Mallett J, Grant-Kels JM. Laptop computer-associated erythema ab igne. Cutis. 2007;80:319-320.
  28. Mohr MR, Scott KA, Pariser RM, et al. Laptop computer-induced erythema ab igne: a case report. Cutis. 2007;79:59-60.
  29. Cantor AS, Bartling SJ. Laptop computer-induced hyperpigmentation. Dermatol Online J. 2018;24:13030/qt6k37r9wm.
  30. Kaptanog˘lu AF, Mullaaziz D. Erythema ab igne in the palmar area induced by smart phone: case report. Turkiye Klin J Med Sci. 2015;35:284-286. doi:10.5336/medsci.2015-46976
  31. Redding KS, Watts AN, Lee J, et al. Space heater-induced bullous erythema ab igne. Cutis. 2017;100:E9-E10.
  32. Goorland J, Edens MA, Baudoin TD. An emergency department presentation of erythema ab igne caused by repeated heater exposure. J La State Med Soc. 2016;168:33-34.
  33. Kokturk A, Kaya TI, Baz K, et al. Bullous erythema ab igne. Dermatol Online J. 2003;9:18.
  34. Brzezinski P, Ismail S, Chiriac A. Radiator-induced erythema ab igne in 8-year-old girl. Rev Chil Pediatr. 2014;85:239-240. doi:10.4067/S0370-41062014000200015
  35. Adams BB. Heated car seat-induced erythema ab igne. Arch Dermatol. 2012;148:265-266. doi:10.1001/archdermatol.2011.2207
  36. Helm TN, Spigel GT, Helm KF. Erythema ab igne caused by a car heater. Cutis. 1997;59:81-82.
  37. Gregory JF, Beute TC. Erythema ab igne. J Spec Oper Med. 2013;13:115-119. doi:10.55460/5AVH-NZHY
  38. Chua S, Chen Q, Lee HY. Erythema ab igne and dermal scarring caused by cupping and moxibustion treatment. J Dtsch Dermatol Ges. 2015;13:337-338. doi:10.1111/ddg.12581
  39. Chen JF, Liu YC, Chen YF, et al. Erythema ab igne after footbath with Chinese herbal remedies. J Chinese Med Assoc. 2011;74:51-53. doi:10.1016/j.jcma.2011.01.009
  40. Baltazar D, Brockman R, Simpson E. Kotatsu-induced erythema ab igne. An Bras Dermatol. 2019;94:253-254. doi:10.1590/abd1806-4841.20198792
  41. Baig M, Byrne F. Erythema ab igne and its relation to spinal pathology. Cureus. 2018;10:e2914. doi:10.7759/cureus.2914
  42. Aria AB, Chen L, Silapunt S. Erythema ab igne from heating pad use: a report of three clinical cases and a differential diagnosis. Cureus. 2018;10:e2635. doi:10.7759/cureus.2635
  43. Milchak M, Smucker J, Chung CG, et al. Erythema ab igne due to heating pad use: a case report and review of clinical presentation, prevention, and complications. Case Rep Med. 2016;1862480. doi:10.1155/2016/1862480
  44. Gmuca S, Yu J, Weiss PF, et al. Erythema ab igne in an adolescent with chronic pain: an alarming cutaneous eruption from heat exposure. Pediatr Emerg Care. 2020;36:e236-e238. doi:10.1097/PEC.0000000000001460
  45. Dizdarevic A, Karim OA, Bygum A. A reddish brown reticulated hyperpigmented erythema on the abdomen of a girl. Erythema ab igne, also known as toasted skin syndrome, caused by a heating pad onthe abdomen. Acta Derm Venereol. 2014;94:365-367. doi:10.2340/00015555-1722
  46. Chatterjee S. Erythema ab igne from prolonged use of a heating pad. Mayo Clin Proc. 2005;80:1500. doi:10.4065/80.11.1500
  47. Waldorf DS, Rast MF, Garofalo VJ. Heating-pad erythematous dermatitis “erythema ab igne.” JAMA. 1971;218:1704. doi:10.1001/jama.1971.03190240056023
  48. South AM, Crispin MK, Marqueling AL, et al. A hyperpigmented reticular rash in a patient on peritoneal dialysis. Perit Dial Int. 2016;36:677-700. doi:10.3747/pdi.2016.00042
  49. Ravindran R. Erythema ab igne in an individual with diabetes and gastroparesis. BMJ Case Rep. 2017;2017:bcr2014203856. doi:10.1136/bcr-2014-203856
  50. Dessinioti C, Katsambas A, Tzavela E, et al. Erythema ab igne in three girls with anorexia nervosa. Pediatr Dermatol. 2016;33:e149-e150. doi:10.1111/pde.12770
  51. Fischer J, Rein K, Erfurt-Berge C, et al. Three cases of erythema ab igne (EAI) in patients with eating disorders. Neuropsychiatr. 2010;24:141-143.
  52. Docx MKF, Simons A, Ramet J, et al. Erythema ab igne in an adolescent with anorexia nervosa. Int J Eat Disord. 2013;46:381-383. doi:10.1002/eat.22075
  53. Turan E, Cimen V, Haytoglu NSK, et al. A case of bullous erythema ab igne accompanied by anemia and subclinical hypothyroidism. Dermatol Online J. 2014;20:223366.
  54. Pavithran K. Erythema ab igne, schizophrenia and thermophilia. Indian J Dermatol Venereol Leprol. 1987;53:181-182.
  55. Dellavelle R, Gillum P. Erythema ab igne following heating/cooling blanket use in the intensive care unit. Cutis. 2000;66:136-138.
  56. Park SY, Kim SM, Yoon TJ. Erythema ab igne caused by weight loss heating pad. Korean J Dermatol. 2007;45:489-491.
  57. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98:75-81. doi:10.1016/j.jdermsci.2020.04.011
  58. Gisondi P, Plaserico S, Bordin C, et al. Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020;34:2499-2504. doi:10.1111/jdv.16774
  59. Manalo IF, Smith MK, Cheeley J, et al. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83:700. doi:10.1016/j.jaad.2020.04.018
  60. Zhao Q, Fang X, Pang Z, et al. COVID‐19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020;34:2505-2510. doi:10.1111/jdv.16778
  61. Akasaka T, Kon S. Two cases of squamous cell carcinoma arising from erythema ab igne. Nihon Hifuka Gakkai Zasshi. 1989;99:735-742.
  62. Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. Arch Dermatol. 1979;115:1226-1228.
  63. Wharton JB, Sheehan DJ, Lesher JL Jr. Squamous cell carcinoma in situ arising in the setting of erythema ab igne. J Drugs Dermatol. 2008;7:488-489.
  64. Wollina U, Helm C, Hansel G, et al. Two cases of erythema ab igne, one with a squamous cell carcinoma. G Ital Dermatol Venereol. 2007;142:415-418.
  65. Rudolph CM, Soyer HP, Wolf P, et al. Squamous cell carcinoma arising in erythema ab igne. Hautarzt. 2000;51:260-263. doi:10.1007/s001050051115
  66. Sigmon JR, Cantrell J, Teague D, et al. Poorly differentiated carcinoma arising in the setting of erythema ab igne. Am J Dermatopathol. 2013;35:676-678. doi:10.1097/DAD.0b013e3182871648
  67. Wharton J, Roffwarg D, Miller J, et al. Cutaneous marginal zone lymphoma arising in the setting of erythema ab igne. J Am Acad Dermatol. 2010;62:1080-1081. doi:10.1016/j.jaad.2009.08.005
  68. Jones CS, Tyring SK, Lee PC, et al. Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol. 1988;124:110-113.
  69. Kim HW, Kim EJ, Park HC, et al. Erythema ab igne successfully treated with low fluenced 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet laser. J Cosmet Laser Ther. 2014;16:147-148. doi:10.3109/14764172.2013.854623
  70. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;62:77-78.
  71. Gianfaldoni S, Gianfaldoni R, Tchernev G, et al. Erythema ab igne successfully treated with mesoglycan and bioflavonoids: a case-report. Open Access Maced J Med Sci. 2017;5:432-435. doi:10.3889/oamjms.2017.123
Issue
Cutis - 111(4)
Issue
Cutis - 111(4)
Page Number
E33-E38
Page Number
E33-E38
Publications
Publications
Topics
Article Type
Display Headline
Erythema Ab Igne: A Clinical Review
Display Headline
Erythema Ab Igne: A Clinical Review
Sections
Inside the Article

Practice Points

  • Erythema ab igne (EAI) is a skin condition caused by chronic exposure to heat; removal of the heat source often will result in self-resolution of the rash.
  • Erythema ab igne can be a sign of underlying illness in patients self-treating chronic pain with application of heat.
  • Recognition and discontinuation of the exposure with close observation are key components in the treatment of EAI.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Orf Virus in Humans: Case Series and Clinical Review

Article Type
Changed
Thu, 09/29/2022 - 07:35
Display Headline
Orf Virus in Humans: Case Series and Clinical Review

A patient presenting with a hand pustule is a phenomenon encountered worldwide requiring careful history-taking. Some occupations, activities, and various religious practices (eg, Eid al-Adha, Passover, Easter) have been implicated worldwide in orf infection. In the United States, orf virus usually is spread from infected animal hosts to humans. Herein, we review the differential for a single hand pustule, which includes both infectious and noninfectious causes. Recognizing orf virus as the etiology of a cutaneous hand pustule in patients is important, as misdiagnosis can lead to unnecessary invasive testing and/or treatments with suboptimal clinical outcomes.

Case Series

When conducting a search for orf virus cases at our institution (University of Iowa Hospitals and Clinics, Iowa City, Iowa), 5 patient cases were identified.

Patient 1—A 27-year-old otherwise healthy woman presented to clinic with a tender red bump on the right ring finger that had been slowly growing over the course of 2 weeks and had recently started to bleed. A social history revealed that she owned several goats, which she frequently milked; 1 of the goats had a cyst on the mouth, which she popped approximately 1 to 2 weeks prior to the appearance of the lesion on the finger. She also endorsed that she owned several cattle and various other animals with which she had frequent contact. A biopsy was obtained with features consistent with orf virus.

Patient 2—A 33-year-old man presented to clinic with a lesion of concern on the left index finger. Several days prior to presentation, the patient had visited the emergency department for swelling and erythema of the same finger after cutting himself with a knife while preparing sheep meat. Radiographs were normal, and the patient was referred to dermatology. In clinic, there was a 0.5-cm fluctuant mass on the distal interphalangeal joint of the third finger. The patient declined a biopsy, and the lesion healed over 4 to 6 weeks without complication.

Patient 3—A 38-year-old man presented to clinic with 2 painless, large, round nodules on the right proximal index finger, with open friable centers noted on physical examination (Figure 1). The patient reported cutting the finger while preparing sheep meat several days prior. The nodules had been present for a few weeks and continued to grow. A punch biopsy revealed evidence of parapoxvirus infection consistent with a diagnosis of orf.

Two erythematous to yellowish, crateriform, exophytic nodules with secondary pustulation, central erosion, and serosanguineous drainage on the right second interphalangeal joint and proximal finger.
FIGURE 1. Two erythematous to yellowish, crateriform, exophytic nodules with secondary pustulation, central erosion, and serosanguineous drainage on the right second interphalangeal joint and proximal finger.

Patient 4—A 48-year-old man was referred to our dermatology clinic for evaluation of a bleeding lesion on the left middle finger. Physical examination revealed an exophytic, friable, ulcerated nodule on the dorsal aspect of the left middle finger (Figure 2). Upon further questioning, the patient mentioned that he handled raw lamb meat after cutting the finger. A punch biopsy was obtained and was consistent with orf virus infection.

A 2-cm, well-defined, erythematous plaque with overlying erosion, serosanguineous drainage, and peripheral hyperpigmentation on the distal third finger.
FIGURE 2. A 2-cm, well-defined, erythematous plaque with overlying erosion, serosanguineous drainage, and peripheral hyperpigmentation on the distal third finger.

Patient 5—A 43-year-old woman presented to clinic with a chronic wound on the mid lower back that was noted to drain and crust over. She thought the lesion was improving, but it had become painful over the last few weeks. A shave biopsy of the lesion was consistent with orf virus. At follow-up, the patient was unable to identify any recent contact with animals.

 

 

Comment

Transmission From Animals to Humans—Orf virus is a member of the Parapoxvirus genus of the Poxviridae family.1 This virus is highly contagious among animals and has been described around the globe. The resulting disease also is known as contagious pustular dermatitis,2 soremuzzle,3 ecthyma contagiosum of sheep,4 and scabby mouth.5 This virus most commonly infects young lambs and manifests as raw to crusty papules, pustules, or vesicles around the mouth and nose of the animal.4 Additional signs include excessive salivation and weight loss or starvation from the inability to suckle because of the lesions.5 Although ecthyma contagiosum infection of sheep and goats has been well known for centuries, human infection was first reported in the literature in 1934.6

Transmission of orf to humans can occur when direct contact with an infected animal exhibiting active lesions occurs.7 Orf virus also can be transmitted through fomites (eg, from knives, wool, buildings, equipment) that previously were in contact with infected animals, making it relevant to ask all farmers about any animals with pustules around the mouth, nose, udders, or other commonly affected areas. Although sanitation efforts are important for prevention, orf virus is hardy, and fomites can remain on surfaces for many months.8 Transmission among animals and from animals to humans frequently occurs; however, human-to-human transmission is less common.9 Ecthyma contagiosum is considered an occupational hazard, with the disease being most prevalent in shepherds, veterinarians, and butchers.1,8 Disease prevalence in these occupations has been reported to be as high as 50%.10 Infections also are seen in patients who attend petting zoos or who slaughter goats and sheep for cultural practices.8

Clinical Characteristics in Humans—The clinical diagnosis of orf is dependent on taking a thorough patient history that includes social, occupational, and religious activities. Development of a nodule or papule on a patient’s hand with recent exposure to fomites or direct contact with a goat or sheep up to 1 week prior is extremely suggestive of an orf virus infection.

Clinically, orf most often begins as an individual papule or nodule on the dorsal surface of the patient’s finger or hand and ranges from completely asymptomatic to pruritic or even painful.1,8 Depending on how the infection was inoculated, lesions can vary in size and number. Other sites that have been reported less frequently include the genitals, legs, axillae, and head.11,12 Lesions are roughly 1 cm in diameter but can vary in size. Ecthyma contagiosum is not a static disease but changes in appearance over the course of infection. Typically, lesions will appear 3 to 7 days after inoculation with the orf virus and will self-resolve 6 to 8 weeks later.

Orf lesions have been described to progress through 6 distinct phases before resolving: maculopapular (erythematous macule or papule forms), targetoid (formation of a necrotic center with red outer halo), acute (lesion begins to weep), regenerative (lesion becomes dry), papilloma (dry crust becomes papillomatous), and regression (skin returns to normal appearance).1,8,9 Each phase of ecthyma contagiosum is unique and will last up to 1 week before progressing. Because of this prolonged clinical course, patients can present at any stage.

Reports of systemic symptoms are uncommon but can include lymphadenopathy, fever, and malaise.13 Although the disease course in immunocompetent individuals is quite mild, immunocompromised patients may experience persistent orf lesions that are painful and can be much larger, with reports of several centimeters in diameter.14

Dermatopathology and Molecular Studies—When a clinical diagnosis is not possible, biopsy or molecular studies can be helpful.8 Histopathology can vary depending on the phase of the lesion. Early stages are characterized by spongiform degeneration of the epidermis with variable vesiculation of the superficial epidermis and eosinophilic cytoplasmic inclusion bodies of keratinocytes (Figure 3). Later stages demonstrate full-thickness necrosis with epidermal balloon degeneration and dense inflammation of the dermis with edema and extravasated erythrocytes from dilated blood vessels. Both early- and late-stage disease commonly show characteristic elongated thin rete ridges.8

Hyperplastic follicles with balloon cell change, perinuclear vacuolization, and surrounding acute and chronic dermatitis
FIGURE 3. A, Hyperplastic follicles with balloon cell change, perinuclear vacuolization, and surrounding acute and chronic dermatitis (H&E, original magnification ×40). B, Perinuclear vacuolization (green arrows) with eosinophilic viral cytoplasmic inclusion bodies (black arrows) and nuclear pseudoinclusion bodies (black circles)(H&E, original magnification ×400).

 

 

Molecular studies are another reliable method for diagnosis, though these are not always readily available. Polymerase chain reaction can be used for sensitive and rapid diagnosis.15 Less commonly, electron microscopy, Western blot, or enzyme-linked immunosorbent assays are used.16 Laboratory studies, such as complete blood cell count with differential, erythrocyte sedimentation rate, and C-reactive protein, often are unnecessary but may be helpful in ruling out other infectious causes. Tissue culture can be considered if bacterial, fungal, or acid-fast bacilli are in the differential; however, no growth will be seen in the case of orf viral infection.

Differential Diagnosis—The differential diagnosis for patients presenting with a large pustule on the hand or fingers can depend on geographic location, as the potential etiology may vary widely around the world. Several zoonotic viral infections other than orf can present with pustular lesions on the hands (Table).17-24

Zoonotic Infections Presenting With a Large Papule or Pustule on the Hands or Fingers

Clinically, infection with these named viruses can be hard to distinguish; however, appropriate social history or polymerase chain reaction can be obtained to differentiate them. Other infectious entities include herpetic whitlow, giant molluscum, and anthrax (eTable).24-26 Biopsy of the lesion with bacterial tissue culture may lead to definitive diagnosis.26

 Other Considerations for Patients Presenting With a Large Papule or Pustule on the Hands or Fingers

Treatment—Because of the self-resolving nature of orf, treatment usually is not needed in immunocompetent patients with a solitary lesion. However, wound care is essential to prevent secondary infections of the lesion. If secondarily infected, topical or oral antibiotics may be prescribed. Immunocompromised individuals are at increased risk for developing large persistent lesions and sometimes require intervention for successful treatment. Several successful treatment methods have been described and include intralesional interferon injections, electrocautery, topical imiquimod, topical cidofovir, and cryotherapy.8,14,27-30 Infections that continue to be refractory to less-invasive treatment can be considered for wide local excision; however, recurrence is possible.8 Vaccinations are available for animals to prevent the spread of infection in the flock, but there are no formulations of vaccines for human use. Prevention of spread to humans can be done through animal vaccination, careful handling of animal products while wearing nonporous gloves, and proper sanitation techniques.

Complications—Orf has an excellent long-term prognosis in immunocompetent patients, as the virus is epitheliotropic, and inoculation does not lead to viremia.2 Although lesions typically are asymptomatic in most patients, complications can occur, especially in immunosuppressed individuals. These complications include systemic symptoms, giant persistent lesions prone to infection or scarring, erysipelas, lymphadenitis, and erythema multiforme.8,31 Common systemic symptoms of ecthyma contagiosum include fever, fatigue, and myalgia. Lymphadenitis can occur along with local swelling and lymphatic streaking. Although erythema multiforme is a rare complication occurring after initial ecthyma contagiosum infection, this hypersensitivity reaction is postulated to be in response to the immunologic clearing of the orf virus.32,33 Patients receiving systemic immunosuppressive medications are at an increased risk of developing complications from infection and may even be required to pause systemic treatment for complete resolution of orf lesions.34 Other cutaneous diseases that decrease the skin’s barrier protection, such as bullous pemphigoid or eczema, also can place patients at an increased risk for complications.35 Although human-to-human orf virus transmission is exceptionally rare, there is a case report of this phenomenon in immunosuppressed patients residing in a burn unit.36 Transplant recipients on immunosuppressive medications also can experience orf lesions with exaggerated presentations that continue to grow up to several centimeters in diameter.31 Long-term prognosis is still good in these patients with appropriate disease recognition and treatment. Reinfection is not uncommon with repeated exposure to the source, but lesions are less severe and resolve faster than with initial infection.1,8

Conclusion

The contagious hand pustule caused by orf virus is a distinct clinical entity that is prevalent worldwide and requires thorough evaluation of the clinical course of the lesion and the patient’s social history. Several zoonotic viral infections have been implicated in this presentation. Although biopsy and molecular studies can be helpful, the expert diagnostician can make a clinical diagnosis with careful attention to social history, geographic location, and cultural practices.

References
  1. Haig DM, Mercer AA. Ovine diseases. orf. Vet Res. 1998;29:311-326.
  2. Glover RE. Contagious pustular dermatitis of the sheep. J Comp Pathol Ther. 1928;41:318-340.
  3. Hardy WT, Price DA. Soremuzzle of sheep. J Am Vet Med Assoc. 1952;120:23-25.
  4. Boughton IB, Hardy WT. Contagious ecthyma (sore mouth) of sheep and goats. J Am Vet Med Assoc. 1934;85:150-178.
  5. Gardiner MR, Craig VMD, Nairn ME. An unusual outbreak of contagious ecthyma (scabby mouth) in sheep. Aust Vet J. 1967;43:163-165.
  6. Newsome IE, Cross F. Sore mouth in sheep transmissible to man. J Am Vet Med Assoc. 1934;84:790-802.
  7. Demiraslan H, Dinc G, Doganay M. An overview of orf virus infection in humans and animals. Recent Pat Anti Infect Drug Discov. 2017;12:21-30.
  8. Bergqvist C, Kurban M, Abbas O. Orf virus infection. Rev Med Virol. 2017;27:E1932.
  9. Duchateau NC, Aerts O, Lambert J. Autoinoculation with orf virus (ecthyma contagiosum). Int J Dermatol. 2014;53:E60-E62.
  10. Paiba GA, Thomas DR, Morgan KL, et al. Orf (contagious pustular dermatitis) in farmworkers: prevalence and risk factors in three areas of England. Vet Rec. 1999;145:7-11
  11. Kandemir H, Ciftcioglu MA, Yilmaz E. Genital orf. Eur J Dermatol. 2008;18:460-461.
  12. Weide B, Metzler G, Eigentler TK, et al. Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. Clin Exp Dermatol. 2009;34:240-242.
  13. Wilkinson JD. Orf: a family with unusual complications. Br J Dermatol. 1977;97:447-450.
  14. Zaharia D, Kanitakis J, Pouteil-Noble C, et al. Rapidly growing orf in a renal transplant recipient: favourable outcome with reduction of immunosuppression and imiquimod. Transpl Int. 2010;23:E62-E64.
  15. Bora DP, Venkatesan G, Bhanuprakash V, et al. TaqMan real-time PCR assay based on DNA polymerase gene for rapid detection of orf infection. J Virol Methods. 2011;178:249-252.
  16. Töndury B, Kühne A, Kutzner H, et al. Molecular diagnostics of parapox virus infections. J Dtsch Dermatol Ges. 2010;8:681-684.
  17. Handler NS, Handler MZ, Rubins A, et al. Milker’s nodule: an occupational infection and threat to the immunocompromised. J Eur Acad Dermatol Venereol. 2018;32:537-541.
  18. Groves RW, Wilson-Jones E, MacDonald DM. Human orf and milkers’ nodule: a clinicopathologic study. J Am Acad Dermatol. 1991;25:706-711.
  19. Bowman KF, Barbery RT, Swango LJ, et al. Cutaneous form of bovine papular stomatitis in man. JAMA. 1981;246;1813-1818.
  20. Nagington J, Lauder IM, Smith JS. Bovine papular stomatitis, pseudocowpox and milker’s nodules. Vet Rec. 1967;79:306-313.
  21. Clark C, McIntyre PG, Evans A, et al. Human sealpox resulting from a seal bite: confirmation that sealpox virus is zoonotic. Br J Dermatol. 2005;152:791-793.
  22. Downie AW, Espana C. A comparative study of tanapox and yaba viruses. J Gen Virol. 1973;19:37-49.
  23. Zimmermann P, Thordsen I, Frangoulidis D, et al. Real-time PCR assay for the detection of tanapox virus and yaba-like disease virus. J Virol Methods. 2005;130:149-153.
  24. Bolognia J, Schaffer J, Cerroni L. Dermatology. 4th ed. Elsevier Saunders; 2018.
  25. Wenner KA, Kenner JR. Anthrax. Dermatol Clin. 2004;22:247-256.
  26. Brachman P, Kaufmann A. Anthrax. In: Evans A, Brachman P, eds. Bacterial Infections of Humans: Epidemiology and Control. 3rd ed. Plenum Publishing; 1998:95.
  27. Ran M, Lee M, Gong J, et al. Oral acyclovir and intralesional interferon injections for treatment of giant pyogenic granuloma-like lesions in an immunocompromised patient with human orf. JAMA Dermatol. 2015;151:1032-1034.
  28. Degraeve C, De Coninck A, Senneseael J, et al. Recurrent contagious ecthyma (orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology. 1999;198:162-163.
  29. Geerinck K, Lukito G, Snoeck R, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001;64:543-549.
  30. Ertekin S, Gurel M, Erdemir A, et al. Systemic interferon alfa injections for the treatment of a giant orf. Cutis. 2017;99:E19-E21.
  31. Hunskaar S. Giant orf in a patient with chronic lymphocytic leukaemia. Br J Dermatol. 1986;114:631-634.
  32. Ozturk P, Sayar H, Karakas T, et al. Erythema multiforme as a result of orf disease. Acta Dermatovenereol Alp Pannonica Adriat. 2012;21:45-46.
  33. Shahmoradi Z, Abtahi-Naeini B, Pourazizi M, et al. Orf disease following ‘eid ul-adha’: a rare cause of erythema multiforme. Int J Prev Med. 2014;5:912-914.
  34. Kostopoulos M, Gerodimos C, Batsila E, et al. Orf disease in a patient with rheumatoid arthritis. Mediterr J Rheumatol. 2018;29:89-91.
  35. Murphy JK, Ralphs IG. Bullous pemphigoid complicating human orf. Br J Dermatol. 1996;134:929-930.
  36. Midilli K, Erkiliç A, Kus¸kucu M, et al. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012. Euro Surveill2013;18:20425.
Article PDF
Author and Disclosure Information

From the Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City.

The authors report no conflict of interest.

The eTable is available in the Appendix online at www.mdedge.com/dermatology.

Correspondence: Jennifer G. Powers, MD, Department of Dermatology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr 40024 PFP, Iowa City, IA 52242 (jennifer-g-powers@uiowa.edu).

Issue
Cutis - 110(1)
Publications
Topics
Page Number
48-52,E4
Sections
Author and Disclosure Information

From the Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City.

The authors report no conflict of interest.

The eTable is available in the Appendix online at www.mdedge.com/dermatology.

Correspondence: Jennifer G. Powers, MD, Department of Dermatology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr 40024 PFP, Iowa City, IA 52242 (jennifer-g-powers@uiowa.edu).

Author and Disclosure Information

From the Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City.

The authors report no conflict of interest.

The eTable is available in the Appendix online at www.mdedge.com/dermatology.

Correspondence: Jennifer G. Powers, MD, Department of Dermatology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr 40024 PFP, Iowa City, IA 52242 (jennifer-g-powers@uiowa.edu).

Article PDF
Article PDF

A patient presenting with a hand pustule is a phenomenon encountered worldwide requiring careful history-taking. Some occupations, activities, and various religious practices (eg, Eid al-Adha, Passover, Easter) have been implicated worldwide in orf infection. In the United States, orf virus usually is spread from infected animal hosts to humans. Herein, we review the differential for a single hand pustule, which includes both infectious and noninfectious causes. Recognizing orf virus as the etiology of a cutaneous hand pustule in patients is important, as misdiagnosis can lead to unnecessary invasive testing and/or treatments with suboptimal clinical outcomes.

Case Series

When conducting a search for orf virus cases at our institution (University of Iowa Hospitals and Clinics, Iowa City, Iowa), 5 patient cases were identified.

Patient 1—A 27-year-old otherwise healthy woman presented to clinic with a tender red bump on the right ring finger that had been slowly growing over the course of 2 weeks and had recently started to bleed. A social history revealed that she owned several goats, which she frequently milked; 1 of the goats had a cyst on the mouth, which she popped approximately 1 to 2 weeks prior to the appearance of the lesion on the finger. She also endorsed that she owned several cattle and various other animals with which she had frequent contact. A biopsy was obtained with features consistent with orf virus.

Patient 2—A 33-year-old man presented to clinic with a lesion of concern on the left index finger. Several days prior to presentation, the patient had visited the emergency department for swelling and erythema of the same finger after cutting himself with a knife while preparing sheep meat. Radiographs were normal, and the patient was referred to dermatology. In clinic, there was a 0.5-cm fluctuant mass on the distal interphalangeal joint of the third finger. The patient declined a biopsy, and the lesion healed over 4 to 6 weeks without complication.

Patient 3—A 38-year-old man presented to clinic with 2 painless, large, round nodules on the right proximal index finger, with open friable centers noted on physical examination (Figure 1). The patient reported cutting the finger while preparing sheep meat several days prior. The nodules had been present for a few weeks and continued to grow. A punch biopsy revealed evidence of parapoxvirus infection consistent with a diagnosis of orf.

Two erythematous to yellowish, crateriform, exophytic nodules with secondary pustulation, central erosion, and serosanguineous drainage on the right second interphalangeal joint and proximal finger.
FIGURE 1. Two erythematous to yellowish, crateriform, exophytic nodules with secondary pustulation, central erosion, and serosanguineous drainage on the right second interphalangeal joint and proximal finger.

Patient 4—A 48-year-old man was referred to our dermatology clinic for evaluation of a bleeding lesion on the left middle finger. Physical examination revealed an exophytic, friable, ulcerated nodule on the dorsal aspect of the left middle finger (Figure 2). Upon further questioning, the patient mentioned that he handled raw lamb meat after cutting the finger. A punch biopsy was obtained and was consistent with orf virus infection.

A 2-cm, well-defined, erythematous plaque with overlying erosion, serosanguineous drainage, and peripheral hyperpigmentation on the distal third finger.
FIGURE 2. A 2-cm, well-defined, erythematous plaque with overlying erosion, serosanguineous drainage, and peripheral hyperpigmentation on the distal third finger.

Patient 5—A 43-year-old woman presented to clinic with a chronic wound on the mid lower back that was noted to drain and crust over. She thought the lesion was improving, but it had become painful over the last few weeks. A shave biopsy of the lesion was consistent with orf virus. At follow-up, the patient was unable to identify any recent contact with animals.

 

 

Comment

Transmission From Animals to Humans—Orf virus is a member of the Parapoxvirus genus of the Poxviridae family.1 This virus is highly contagious among animals and has been described around the globe. The resulting disease also is known as contagious pustular dermatitis,2 soremuzzle,3 ecthyma contagiosum of sheep,4 and scabby mouth.5 This virus most commonly infects young lambs and manifests as raw to crusty papules, pustules, or vesicles around the mouth and nose of the animal.4 Additional signs include excessive salivation and weight loss or starvation from the inability to suckle because of the lesions.5 Although ecthyma contagiosum infection of sheep and goats has been well known for centuries, human infection was first reported in the literature in 1934.6

Transmission of orf to humans can occur when direct contact with an infected animal exhibiting active lesions occurs.7 Orf virus also can be transmitted through fomites (eg, from knives, wool, buildings, equipment) that previously were in contact with infected animals, making it relevant to ask all farmers about any animals with pustules around the mouth, nose, udders, or other commonly affected areas. Although sanitation efforts are important for prevention, orf virus is hardy, and fomites can remain on surfaces for many months.8 Transmission among animals and from animals to humans frequently occurs; however, human-to-human transmission is less common.9 Ecthyma contagiosum is considered an occupational hazard, with the disease being most prevalent in shepherds, veterinarians, and butchers.1,8 Disease prevalence in these occupations has been reported to be as high as 50%.10 Infections also are seen in patients who attend petting zoos or who slaughter goats and sheep for cultural practices.8

Clinical Characteristics in Humans—The clinical diagnosis of orf is dependent on taking a thorough patient history that includes social, occupational, and religious activities. Development of a nodule or papule on a patient’s hand with recent exposure to fomites or direct contact with a goat or sheep up to 1 week prior is extremely suggestive of an orf virus infection.

Clinically, orf most often begins as an individual papule or nodule on the dorsal surface of the patient’s finger or hand and ranges from completely asymptomatic to pruritic or even painful.1,8 Depending on how the infection was inoculated, lesions can vary in size and number. Other sites that have been reported less frequently include the genitals, legs, axillae, and head.11,12 Lesions are roughly 1 cm in diameter but can vary in size. Ecthyma contagiosum is not a static disease but changes in appearance over the course of infection. Typically, lesions will appear 3 to 7 days after inoculation with the orf virus and will self-resolve 6 to 8 weeks later.

Orf lesions have been described to progress through 6 distinct phases before resolving: maculopapular (erythematous macule or papule forms), targetoid (formation of a necrotic center with red outer halo), acute (lesion begins to weep), regenerative (lesion becomes dry), papilloma (dry crust becomes papillomatous), and regression (skin returns to normal appearance).1,8,9 Each phase of ecthyma contagiosum is unique and will last up to 1 week before progressing. Because of this prolonged clinical course, patients can present at any stage.

Reports of systemic symptoms are uncommon but can include lymphadenopathy, fever, and malaise.13 Although the disease course in immunocompetent individuals is quite mild, immunocompromised patients may experience persistent orf lesions that are painful and can be much larger, with reports of several centimeters in diameter.14

Dermatopathology and Molecular Studies—When a clinical diagnosis is not possible, biopsy or molecular studies can be helpful.8 Histopathology can vary depending on the phase of the lesion. Early stages are characterized by spongiform degeneration of the epidermis with variable vesiculation of the superficial epidermis and eosinophilic cytoplasmic inclusion bodies of keratinocytes (Figure 3). Later stages demonstrate full-thickness necrosis with epidermal balloon degeneration and dense inflammation of the dermis with edema and extravasated erythrocytes from dilated blood vessels. Both early- and late-stage disease commonly show characteristic elongated thin rete ridges.8

Hyperplastic follicles with balloon cell change, perinuclear vacuolization, and surrounding acute and chronic dermatitis
FIGURE 3. A, Hyperplastic follicles with balloon cell change, perinuclear vacuolization, and surrounding acute and chronic dermatitis (H&E, original magnification ×40). B, Perinuclear vacuolization (green arrows) with eosinophilic viral cytoplasmic inclusion bodies (black arrows) and nuclear pseudoinclusion bodies (black circles)(H&E, original magnification ×400).

 

 

Molecular studies are another reliable method for diagnosis, though these are not always readily available. Polymerase chain reaction can be used for sensitive and rapid diagnosis.15 Less commonly, electron microscopy, Western blot, or enzyme-linked immunosorbent assays are used.16 Laboratory studies, such as complete blood cell count with differential, erythrocyte sedimentation rate, and C-reactive protein, often are unnecessary but may be helpful in ruling out other infectious causes. Tissue culture can be considered if bacterial, fungal, or acid-fast bacilli are in the differential; however, no growth will be seen in the case of orf viral infection.

Differential Diagnosis—The differential diagnosis for patients presenting with a large pustule on the hand or fingers can depend on geographic location, as the potential etiology may vary widely around the world. Several zoonotic viral infections other than orf can present with pustular lesions on the hands (Table).17-24

Zoonotic Infections Presenting With a Large Papule or Pustule on the Hands or Fingers

Clinically, infection with these named viruses can be hard to distinguish; however, appropriate social history or polymerase chain reaction can be obtained to differentiate them. Other infectious entities include herpetic whitlow, giant molluscum, and anthrax (eTable).24-26 Biopsy of the lesion with bacterial tissue culture may lead to definitive diagnosis.26

 Other Considerations for Patients Presenting With a Large Papule or Pustule on the Hands or Fingers

Treatment—Because of the self-resolving nature of orf, treatment usually is not needed in immunocompetent patients with a solitary lesion. However, wound care is essential to prevent secondary infections of the lesion. If secondarily infected, topical or oral antibiotics may be prescribed. Immunocompromised individuals are at increased risk for developing large persistent lesions and sometimes require intervention for successful treatment. Several successful treatment methods have been described and include intralesional interferon injections, electrocautery, topical imiquimod, topical cidofovir, and cryotherapy.8,14,27-30 Infections that continue to be refractory to less-invasive treatment can be considered for wide local excision; however, recurrence is possible.8 Vaccinations are available for animals to prevent the spread of infection in the flock, but there are no formulations of vaccines for human use. Prevention of spread to humans can be done through animal vaccination, careful handling of animal products while wearing nonporous gloves, and proper sanitation techniques.

Complications—Orf has an excellent long-term prognosis in immunocompetent patients, as the virus is epitheliotropic, and inoculation does not lead to viremia.2 Although lesions typically are asymptomatic in most patients, complications can occur, especially in immunosuppressed individuals. These complications include systemic symptoms, giant persistent lesions prone to infection or scarring, erysipelas, lymphadenitis, and erythema multiforme.8,31 Common systemic symptoms of ecthyma contagiosum include fever, fatigue, and myalgia. Lymphadenitis can occur along with local swelling and lymphatic streaking. Although erythema multiforme is a rare complication occurring after initial ecthyma contagiosum infection, this hypersensitivity reaction is postulated to be in response to the immunologic clearing of the orf virus.32,33 Patients receiving systemic immunosuppressive medications are at an increased risk of developing complications from infection and may even be required to pause systemic treatment for complete resolution of orf lesions.34 Other cutaneous diseases that decrease the skin’s barrier protection, such as bullous pemphigoid or eczema, also can place patients at an increased risk for complications.35 Although human-to-human orf virus transmission is exceptionally rare, there is a case report of this phenomenon in immunosuppressed patients residing in a burn unit.36 Transplant recipients on immunosuppressive medications also can experience orf lesions with exaggerated presentations that continue to grow up to several centimeters in diameter.31 Long-term prognosis is still good in these patients with appropriate disease recognition and treatment. Reinfection is not uncommon with repeated exposure to the source, but lesions are less severe and resolve faster than with initial infection.1,8

Conclusion

The contagious hand pustule caused by orf virus is a distinct clinical entity that is prevalent worldwide and requires thorough evaluation of the clinical course of the lesion and the patient’s social history. Several zoonotic viral infections have been implicated in this presentation. Although biopsy and molecular studies can be helpful, the expert diagnostician can make a clinical diagnosis with careful attention to social history, geographic location, and cultural practices.

A patient presenting with a hand pustule is a phenomenon encountered worldwide requiring careful history-taking. Some occupations, activities, and various religious practices (eg, Eid al-Adha, Passover, Easter) have been implicated worldwide in orf infection. In the United States, orf virus usually is spread from infected animal hosts to humans. Herein, we review the differential for a single hand pustule, which includes both infectious and noninfectious causes. Recognizing orf virus as the etiology of a cutaneous hand pustule in patients is important, as misdiagnosis can lead to unnecessary invasive testing and/or treatments with suboptimal clinical outcomes.

Case Series

When conducting a search for orf virus cases at our institution (University of Iowa Hospitals and Clinics, Iowa City, Iowa), 5 patient cases were identified.

Patient 1—A 27-year-old otherwise healthy woman presented to clinic with a tender red bump on the right ring finger that had been slowly growing over the course of 2 weeks and had recently started to bleed. A social history revealed that she owned several goats, which she frequently milked; 1 of the goats had a cyst on the mouth, which she popped approximately 1 to 2 weeks prior to the appearance of the lesion on the finger. She also endorsed that she owned several cattle and various other animals with which she had frequent contact. A biopsy was obtained with features consistent with orf virus.

Patient 2—A 33-year-old man presented to clinic with a lesion of concern on the left index finger. Several days prior to presentation, the patient had visited the emergency department for swelling and erythema of the same finger after cutting himself with a knife while preparing sheep meat. Radiographs were normal, and the patient was referred to dermatology. In clinic, there was a 0.5-cm fluctuant mass on the distal interphalangeal joint of the third finger. The patient declined a biopsy, and the lesion healed over 4 to 6 weeks without complication.

Patient 3—A 38-year-old man presented to clinic with 2 painless, large, round nodules on the right proximal index finger, with open friable centers noted on physical examination (Figure 1). The patient reported cutting the finger while preparing sheep meat several days prior. The nodules had been present for a few weeks and continued to grow. A punch biopsy revealed evidence of parapoxvirus infection consistent with a diagnosis of orf.

Two erythematous to yellowish, crateriform, exophytic nodules with secondary pustulation, central erosion, and serosanguineous drainage on the right second interphalangeal joint and proximal finger.
FIGURE 1. Two erythematous to yellowish, crateriform, exophytic nodules with secondary pustulation, central erosion, and serosanguineous drainage on the right second interphalangeal joint and proximal finger.

Patient 4—A 48-year-old man was referred to our dermatology clinic for evaluation of a bleeding lesion on the left middle finger. Physical examination revealed an exophytic, friable, ulcerated nodule on the dorsal aspect of the left middle finger (Figure 2). Upon further questioning, the patient mentioned that he handled raw lamb meat after cutting the finger. A punch biopsy was obtained and was consistent with orf virus infection.

A 2-cm, well-defined, erythematous plaque with overlying erosion, serosanguineous drainage, and peripheral hyperpigmentation on the distal third finger.
FIGURE 2. A 2-cm, well-defined, erythematous plaque with overlying erosion, serosanguineous drainage, and peripheral hyperpigmentation on the distal third finger.

Patient 5—A 43-year-old woman presented to clinic with a chronic wound on the mid lower back that was noted to drain and crust over. She thought the lesion was improving, but it had become painful over the last few weeks. A shave biopsy of the lesion was consistent with orf virus. At follow-up, the patient was unable to identify any recent contact with animals.

 

 

Comment

Transmission From Animals to Humans—Orf virus is a member of the Parapoxvirus genus of the Poxviridae family.1 This virus is highly contagious among animals and has been described around the globe. The resulting disease also is known as contagious pustular dermatitis,2 soremuzzle,3 ecthyma contagiosum of sheep,4 and scabby mouth.5 This virus most commonly infects young lambs and manifests as raw to crusty papules, pustules, or vesicles around the mouth and nose of the animal.4 Additional signs include excessive salivation and weight loss or starvation from the inability to suckle because of the lesions.5 Although ecthyma contagiosum infection of sheep and goats has been well known for centuries, human infection was first reported in the literature in 1934.6

Transmission of orf to humans can occur when direct contact with an infected animal exhibiting active lesions occurs.7 Orf virus also can be transmitted through fomites (eg, from knives, wool, buildings, equipment) that previously were in contact with infected animals, making it relevant to ask all farmers about any animals with pustules around the mouth, nose, udders, or other commonly affected areas. Although sanitation efforts are important for prevention, orf virus is hardy, and fomites can remain on surfaces for many months.8 Transmission among animals and from animals to humans frequently occurs; however, human-to-human transmission is less common.9 Ecthyma contagiosum is considered an occupational hazard, with the disease being most prevalent in shepherds, veterinarians, and butchers.1,8 Disease prevalence in these occupations has been reported to be as high as 50%.10 Infections also are seen in patients who attend petting zoos or who slaughter goats and sheep for cultural practices.8

Clinical Characteristics in Humans—The clinical diagnosis of orf is dependent on taking a thorough patient history that includes social, occupational, and religious activities. Development of a nodule or papule on a patient’s hand with recent exposure to fomites or direct contact with a goat or sheep up to 1 week prior is extremely suggestive of an orf virus infection.

Clinically, orf most often begins as an individual papule or nodule on the dorsal surface of the patient’s finger or hand and ranges from completely asymptomatic to pruritic or even painful.1,8 Depending on how the infection was inoculated, lesions can vary in size and number. Other sites that have been reported less frequently include the genitals, legs, axillae, and head.11,12 Lesions are roughly 1 cm in diameter but can vary in size. Ecthyma contagiosum is not a static disease but changes in appearance over the course of infection. Typically, lesions will appear 3 to 7 days after inoculation with the orf virus and will self-resolve 6 to 8 weeks later.

Orf lesions have been described to progress through 6 distinct phases before resolving: maculopapular (erythematous macule or papule forms), targetoid (formation of a necrotic center with red outer halo), acute (lesion begins to weep), regenerative (lesion becomes dry), papilloma (dry crust becomes papillomatous), and regression (skin returns to normal appearance).1,8,9 Each phase of ecthyma contagiosum is unique and will last up to 1 week before progressing. Because of this prolonged clinical course, patients can present at any stage.

Reports of systemic symptoms are uncommon but can include lymphadenopathy, fever, and malaise.13 Although the disease course in immunocompetent individuals is quite mild, immunocompromised patients may experience persistent orf lesions that are painful and can be much larger, with reports of several centimeters in diameter.14

Dermatopathology and Molecular Studies—When a clinical diagnosis is not possible, biopsy or molecular studies can be helpful.8 Histopathology can vary depending on the phase of the lesion. Early stages are characterized by spongiform degeneration of the epidermis with variable vesiculation of the superficial epidermis and eosinophilic cytoplasmic inclusion bodies of keratinocytes (Figure 3). Later stages demonstrate full-thickness necrosis with epidermal balloon degeneration and dense inflammation of the dermis with edema and extravasated erythrocytes from dilated blood vessels. Both early- and late-stage disease commonly show characteristic elongated thin rete ridges.8

Hyperplastic follicles with balloon cell change, perinuclear vacuolization, and surrounding acute and chronic dermatitis
FIGURE 3. A, Hyperplastic follicles with balloon cell change, perinuclear vacuolization, and surrounding acute and chronic dermatitis (H&E, original magnification ×40). B, Perinuclear vacuolization (green arrows) with eosinophilic viral cytoplasmic inclusion bodies (black arrows) and nuclear pseudoinclusion bodies (black circles)(H&E, original magnification ×400).

 

 

Molecular studies are another reliable method for diagnosis, though these are not always readily available. Polymerase chain reaction can be used for sensitive and rapid diagnosis.15 Less commonly, electron microscopy, Western blot, or enzyme-linked immunosorbent assays are used.16 Laboratory studies, such as complete blood cell count with differential, erythrocyte sedimentation rate, and C-reactive protein, often are unnecessary but may be helpful in ruling out other infectious causes. Tissue culture can be considered if bacterial, fungal, or acid-fast bacilli are in the differential; however, no growth will be seen in the case of orf viral infection.

Differential Diagnosis—The differential diagnosis for patients presenting with a large pustule on the hand or fingers can depend on geographic location, as the potential etiology may vary widely around the world. Several zoonotic viral infections other than orf can present with pustular lesions on the hands (Table).17-24

Zoonotic Infections Presenting With a Large Papule or Pustule on the Hands or Fingers

Clinically, infection with these named viruses can be hard to distinguish; however, appropriate social history or polymerase chain reaction can be obtained to differentiate them. Other infectious entities include herpetic whitlow, giant molluscum, and anthrax (eTable).24-26 Biopsy of the lesion with bacterial tissue culture may lead to definitive diagnosis.26

 Other Considerations for Patients Presenting With a Large Papule or Pustule on the Hands or Fingers

Treatment—Because of the self-resolving nature of orf, treatment usually is not needed in immunocompetent patients with a solitary lesion. However, wound care is essential to prevent secondary infections of the lesion. If secondarily infected, topical or oral antibiotics may be prescribed. Immunocompromised individuals are at increased risk for developing large persistent lesions and sometimes require intervention for successful treatment. Several successful treatment methods have been described and include intralesional interferon injections, electrocautery, topical imiquimod, topical cidofovir, and cryotherapy.8,14,27-30 Infections that continue to be refractory to less-invasive treatment can be considered for wide local excision; however, recurrence is possible.8 Vaccinations are available for animals to prevent the spread of infection in the flock, but there are no formulations of vaccines for human use. Prevention of spread to humans can be done through animal vaccination, careful handling of animal products while wearing nonporous gloves, and proper sanitation techniques.

Complications—Orf has an excellent long-term prognosis in immunocompetent patients, as the virus is epitheliotropic, and inoculation does not lead to viremia.2 Although lesions typically are asymptomatic in most patients, complications can occur, especially in immunosuppressed individuals. These complications include systemic symptoms, giant persistent lesions prone to infection or scarring, erysipelas, lymphadenitis, and erythema multiforme.8,31 Common systemic symptoms of ecthyma contagiosum include fever, fatigue, and myalgia. Lymphadenitis can occur along with local swelling and lymphatic streaking. Although erythema multiforme is a rare complication occurring after initial ecthyma contagiosum infection, this hypersensitivity reaction is postulated to be in response to the immunologic clearing of the orf virus.32,33 Patients receiving systemic immunosuppressive medications are at an increased risk of developing complications from infection and may even be required to pause systemic treatment for complete resolution of orf lesions.34 Other cutaneous diseases that decrease the skin’s barrier protection, such as bullous pemphigoid or eczema, also can place patients at an increased risk for complications.35 Although human-to-human orf virus transmission is exceptionally rare, there is a case report of this phenomenon in immunosuppressed patients residing in a burn unit.36 Transplant recipients on immunosuppressive medications also can experience orf lesions with exaggerated presentations that continue to grow up to several centimeters in diameter.31 Long-term prognosis is still good in these patients with appropriate disease recognition and treatment. Reinfection is not uncommon with repeated exposure to the source, but lesions are less severe and resolve faster than with initial infection.1,8

Conclusion

The contagious hand pustule caused by orf virus is a distinct clinical entity that is prevalent worldwide and requires thorough evaluation of the clinical course of the lesion and the patient’s social history. Several zoonotic viral infections have been implicated in this presentation. Although biopsy and molecular studies can be helpful, the expert diagnostician can make a clinical diagnosis with careful attention to social history, geographic location, and cultural practices.

References
  1. Haig DM, Mercer AA. Ovine diseases. orf. Vet Res. 1998;29:311-326.
  2. Glover RE. Contagious pustular dermatitis of the sheep. J Comp Pathol Ther. 1928;41:318-340.
  3. Hardy WT, Price DA. Soremuzzle of sheep. J Am Vet Med Assoc. 1952;120:23-25.
  4. Boughton IB, Hardy WT. Contagious ecthyma (sore mouth) of sheep and goats. J Am Vet Med Assoc. 1934;85:150-178.
  5. Gardiner MR, Craig VMD, Nairn ME. An unusual outbreak of contagious ecthyma (scabby mouth) in sheep. Aust Vet J. 1967;43:163-165.
  6. Newsome IE, Cross F. Sore mouth in sheep transmissible to man. J Am Vet Med Assoc. 1934;84:790-802.
  7. Demiraslan H, Dinc G, Doganay M. An overview of orf virus infection in humans and animals. Recent Pat Anti Infect Drug Discov. 2017;12:21-30.
  8. Bergqvist C, Kurban M, Abbas O. Orf virus infection. Rev Med Virol. 2017;27:E1932.
  9. Duchateau NC, Aerts O, Lambert J. Autoinoculation with orf virus (ecthyma contagiosum). Int J Dermatol. 2014;53:E60-E62.
  10. Paiba GA, Thomas DR, Morgan KL, et al. Orf (contagious pustular dermatitis) in farmworkers: prevalence and risk factors in three areas of England. Vet Rec. 1999;145:7-11
  11. Kandemir H, Ciftcioglu MA, Yilmaz E. Genital orf. Eur J Dermatol. 2008;18:460-461.
  12. Weide B, Metzler G, Eigentler TK, et al. Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. Clin Exp Dermatol. 2009;34:240-242.
  13. Wilkinson JD. Orf: a family with unusual complications. Br J Dermatol. 1977;97:447-450.
  14. Zaharia D, Kanitakis J, Pouteil-Noble C, et al. Rapidly growing orf in a renal transplant recipient: favourable outcome with reduction of immunosuppression and imiquimod. Transpl Int. 2010;23:E62-E64.
  15. Bora DP, Venkatesan G, Bhanuprakash V, et al. TaqMan real-time PCR assay based on DNA polymerase gene for rapid detection of orf infection. J Virol Methods. 2011;178:249-252.
  16. Töndury B, Kühne A, Kutzner H, et al. Molecular diagnostics of parapox virus infections. J Dtsch Dermatol Ges. 2010;8:681-684.
  17. Handler NS, Handler MZ, Rubins A, et al. Milker’s nodule: an occupational infection and threat to the immunocompromised. J Eur Acad Dermatol Venereol. 2018;32:537-541.
  18. Groves RW, Wilson-Jones E, MacDonald DM. Human orf and milkers’ nodule: a clinicopathologic study. J Am Acad Dermatol. 1991;25:706-711.
  19. Bowman KF, Barbery RT, Swango LJ, et al. Cutaneous form of bovine papular stomatitis in man. JAMA. 1981;246;1813-1818.
  20. Nagington J, Lauder IM, Smith JS. Bovine papular stomatitis, pseudocowpox and milker’s nodules. Vet Rec. 1967;79:306-313.
  21. Clark C, McIntyre PG, Evans A, et al. Human sealpox resulting from a seal bite: confirmation that sealpox virus is zoonotic. Br J Dermatol. 2005;152:791-793.
  22. Downie AW, Espana C. A comparative study of tanapox and yaba viruses. J Gen Virol. 1973;19:37-49.
  23. Zimmermann P, Thordsen I, Frangoulidis D, et al. Real-time PCR assay for the detection of tanapox virus and yaba-like disease virus. J Virol Methods. 2005;130:149-153.
  24. Bolognia J, Schaffer J, Cerroni L. Dermatology. 4th ed. Elsevier Saunders; 2018.
  25. Wenner KA, Kenner JR. Anthrax. Dermatol Clin. 2004;22:247-256.
  26. Brachman P, Kaufmann A. Anthrax. In: Evans A, Brachman P, eds. Bacterial Infections of Humans: Epidemiology and Control. 3rd ed. Plenum Publishing; 1998:95.
  27. Ran M, Lee M, Gong J, et al. Oral acyclovir and intralesional interferon injections for treatment of giant pyogenic granuloma-like lesions in an immunocompromised patient with human orf. JAMA Dermatol. 2015;151:1032-1034.
  28. Degraeve C, De Coninck A, Senneseael J, et al. Recurrent contagious ecthyma (orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology. 1999;198:162-163.
  29. Geerinck K, Lukito G, Snoeck R, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001;64:543-549.
  30. Ertekin S, Gurel M, Erdemir A, et al. Systemic interferon alfa injections for the treatment of a giant orf. Cutis. 2017;99:E19-E21.
  31. Hunskaar S. Giant orf in a patient with chronic lymphocytic leukaemia. Br J Dermatol. 1986;114:631-634.
  32. Ozturk P, Sayar H, Karakas T, et al. Erythema multiforme as a result of orf disease. Acta Dermatovenereol Alp Pannonica Adriat. 2012;21:45-46.
  33. Shahmoradi Z, Abtahi-Naeini B, Pourazizi M, et al. Orf disease following ‘eid ul-adha’: a rare cause of erythema multiforme. Int J Prev Med. 2014;5:912-914.
  34. Kostopoulos M, Gerodimos C, Batsila E, et al. Orf disease in a patient with rheumatoid arthritis. Mediterr J Rheumatol. 2018;29:89-91.
  35. Murphy JK, Ralphs IG. Bullous pemphigoid complicating human orf. Br J Dermatol. 1996;134:929-930.
  36. Midilli K, Erkiliç A, Kus¸kucu M, et al. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012. Euro Surveill2013;18:20425.
References
  1. Haig DM, Mercer AA. Ovine diseases. orf. Vet Res. 1998;29:311-326.
  2. Glover RE. Contagious pustular dermatitis of the sheep. J Comp Pathol Ther. 1928;41:318-340.
  3. Hardy WT, Price DA. Soremuzzle of sheep. J Am Vet Med Assoc. 1952;120:23-25.
  4. Boughton IB, Hardy WT. Contagious ecthyma (sore mouth) of sheep and goats. J Am Vet Med Assoc. 1934;85:150-178.
  5. Gardiner MR, Craig VMD, Nairn ME. An unusual outbreak of contagious ecthyma (scabby mouth) in sheep. Aust Vet J. 1967;43:163-165.
  6. Newsome IE, Cross F. Sore mouth in sheep transmissible to man. J Am Vet Med Assoc. 1934;84:790-802.
  7. Demiraslan H, Dinc G, Doganay M. An overview of orf virus infection in humans and animals. Recent Pat Anti Infect Drug Discov. 2017;12:21-30.
  8. Bergqvist C, Kurban M, Abbas O. Orf virus infection. Rev Med Virol. 2017;27:E1932.
  9. Duchateau NC, Aerts O, Lambert J. Autoinoculation with orf virus (ecthyma contagiosum). Int J Dermatol. 2014;53:E60-E62.
  10. Paiba GA, Thomas DR, Morgan KL, et al. Orf (contagious pustular dermatitis) in farmworkers: prevalence and risk factors in three areas of England. Vet Rec. 1999;145:7-11
  11. Kandemir H, Ciftcioglu MA, Yilmaz E. Genital orf. Eur J Dermatol. 2008;18:460-461.
  12. Weide B, Metzler G, Eigentler TK, et al. Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. Clin Exp Dermatol. 2009;34:240-242.
  13. Wilkinson JD. Orf: a family with unusual complications. Br J Dermatol. 1977;97:447-450.
  14. Zaharia D, Kanitakis J, Pouteil-Noble C, et al. Rapidly growing orf in a renal transplant recipient: favourable outcome with reduction of immunosuppression and imiquimod. Transpl Int. 2010;23:E62-E64.
  15. Bora DP, Venkatesan G, Bhanuprakash V, et al. TaqMan real-time PCR assay based on DNA polymerase gene for rapid detection of orf infection. J Virol Methods. 2011;178:249-252.
  16. Töndury B, Kühne A, Kutzner H, et al. Molecular diagnostics of parapox virus infections. J Dtsch Dermatol Ges. 2010;8:681-684.
  17. Handler NS, Handler MZ, Rubins A, et al. Milker’s nodule: an occupational infection and threat to the immunocompromised. J Eur Acad Dermatol Venereol. 2018;32:537-541.
  18. Groves RW, Wilson-Jones E, MacDonald DM. Human orf and milkers’ nodule: a clinicopathologic study. J Am Acad Dermatol. 1991;25:706-711.
  19. Bowman KF, Barbery RT, Swango LJ, et al. Cutaneous form of bovine papular stomatitis in man. JAMA. 1981;246;1813-1818.
  20. Nagington J, Lauder IM, Smith JS. Bovine papular stomatitis, pseudocowpox and milker’s nodules. Vet Rec. 1967;79:306-313.
  21. Clark C, McIntyre PG, Evans A, et al. Human sealpox resulting from a seal bite: confirmation that sealpox virus is zoonotic. Br J Dermatol. 2005;152:791-793.
  22. Downie AW, Espana C. A comparative study of tanapox and yaba viruses. J Gen Virol. 1973;19:37-49.
  23. Zimmermann P, Thordsen I, Frangoulidis D, et al. Real-time PCR assay for the detection of tanapox virus and yaba-like disease virus. J Virol Methods. 2005;130:149-153.
  24. Bolognia J, Schaffer J, Cerroni L. Dermatology. 4th ed. Elsevier Saunders; 2018.
  25. Wenner KA, Kenner JR. Anthrax. Dermatol Clin. 2004;22:247-256.
  26. Brachman P, Kaufmann A. Anthrax. In: Evans A, Brachman P, eds. Bacterial Infections of Humans: Epidemiology and Control. 3rd ed. Plenum Publishing; 1998:95.
  27. Ran M, Lee M, Gong J, et al. Oral acyclovir and intralesional interferon injections for treatment of giant pyogenic granuloma-like lesions in an immunocompromised patient with human orf. JAMA Dermatol. 2015;151:1032-1034.
  28. Degraeve C, De Coninck A, Senneseael J, et al. Recurrent contagious ecthyma (orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology. 1999;198:162-163.
  29. Geerinck K, Lukito G, Snoeck R, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001;64:543-549.
  30. Ertekin S, Gurel M, Erdemir A, et al. Systemic interferon alfa injections for the treatment of a giant orf. Cutis. 2017;99:E19-E21.
  31. Hunskaar S. Giant orf in a patient with chronic lymphocytic leukaemia. Br J Dermatol. 1986;114:631-634.
  32. Ozturk P, Sayar H, Karakas T, et al. Erythema multiforme as a result of orf disease. Acta Dermatovenereol Alp Pannonica Adriat. 2012;21:45-46.
  33. Shahmoradi Z, Abtahi-Naeini B, Pourazizi M, et al. Orf disease following ‘eid ul-adha’: a rare cause of erythema multiforme. Int J Prev Med. 2014;5:912-914.
  34. Kostopoulos M, Gerodimos C, Batsila E, et al. Orf disease in a patient with rheumatoid arthritis. Mediterr J Rheumatol. 2018;29:89-91.
  35. Murphy JK, Ralphs IG. Bullous pemphigoid complicating human orf. Br J Dermatol. 1996;134:929-930.
  36. Midilli K, Erkiliç A, Kus¸kucu M, et al. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012. Euro Surveill2013;18:20425.
Issue
Cutis - 110(1)
Issue
Cutis - 110(1)
Page Number
48-52,E4
Page Number
48-52,E4
Publications
Publications
Topics
Article Type
Display Headline
Orf Virus in Humans: Case Series and Clinical Review
Display Headline
Orf Virus in Humans: Case Series and Clinical Review
Sections
Inside the Article

Practice Points

  • Ecthyma contagiosum is a discrete clinical entity that occurs worldwide and demands careful attention to clinical course and social history.
  • Ecthyma contagiosum is caused by orf virus, an epitheliotropic zoonotic infection that spreads from ruminants to humans.
  • Early and rapid diagnosis of this classic condition is critical to prevent unnecessary biopsies or extensive testing, and determination of etiology can be important in preventing reinfection or spread to other humans by the same infected animal. 
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Asymptomatic Transient Lingual Hyperpigmentation

Article Type
Changed
Mon, 12/07/2020 - 15:18
Display Headline
Asymptomatic Transient Lingual Hyperpigmentation

The Diagnosis: Pseudo-Black Hairy Tongue

Pseudo-black hairy tongue is a benign and painless disorder characterized by transient hyperpigmentation of the tongue with a substance that can be easily scraped off. In this case, the patient's lingual discoloration was secondary to the ingestion of bismuth salicylate. The phenomenon is thought to occur due to a reaction between bismuth and sulfur-containing compounds in the saliva, resulting in the characteristic black substance on the surface of the tongue that nestles between the lingual papillae.1 An associated feature may include black stools. Other etiologic factors involved in pseudo-black hairy tongue include food coloring, tobacco, and other drugs such antibiotics and antidepressants.2  

The differential diagnosis of lingual hyperpigmentation includes lingua villosa nigra (also known as black hairy tongue), pigmented fungiform papillae of the tongue, acanthosis nigricans, and oral hairy leukoplakia. Lingua villosa nigra is a similar condition in which individuals present with a black tongue; however, the tongue also appears hairy. The tongue may appear as other colors such as brown, yellow, or green. Patients additionally may have symptoms of burning, dysgeusia, halitosis, or gagging. Poor oral hygiene, xerostomia, use of tobacco or alcohol, and different medications including antibiotics and antipsychotic medications increase the risk for developing lingua villosa nigra.2,3 This condition is distinguished from pseudo-black hairy tongue by proliferation and elongation of the filiform papillae.3 Pigmented fungiform papillae of the tongue is a normal variant of tongue morphology, is more common in individuals with darker skin types, and primarily affects the lateral aspect and apex of the tongue.4 Acanthosis nigricans can appear in the oral cavity as multiple pigmented papillary lesions on the dorsal and lateral regions of the tongue and frequently involves the lips; this condition may be associated with metabolic disorders or underlying malignancy.2,3 Oral hairy leukoplakia is caused by Epstein-Barr virus infection and typically presents as white plaques on the dorsal and ventral surfaces of the tongue; this condition largely is found in immunocompromised patients.5

In our patient there was an acute onset of tongue discoloration associated with ingestion of bismuth salicylate, no hypertrophy or lengthening of the lingual papillae, and no involvement of the patient's lips, which was consistent with the diagnosis of pseudo-black hairy tongue. Pseudo-black hairy tongue is transient and treated by discontinuation of offending agents and proper hygiene practices.

References
  1. Bradley B, Singleton M, Lin Wan Po A. Bismuth toxicity--a reassessment. J Clin Pharm Ther. 1989;14:423-441.
  2. Gurvits GE, Tan A. Black hairy tongue syndrome. World J Gastroenterol. 2014;20:10845-10850.
  3. Schlager E, St Claire C, Ashack K, et al. Black hairy tongue: predisposing factors, diagnosis, and treatment. Am J Clin Dermatol. 2017;18:563-569.  
  4. Mangold AR, Torgerson RR, Rogers RS. Diseases of the tongue. Clin Dermatol. 2016;34:458-469.
  5. Husak R, Garbe C, Orfanos CE. Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol. 1996;35:928-934.
Article PDF
Author and Disclosure Information

Ms. Patel and Dr. Hsiao are from the Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. Dr. Hsiao also is from the Division of Dermatology. Dr. Harview is from Harbor-UCLA Medical Center Graduate Medical Education, Torrance, California.

The authors report no conflict of interest.  

Correspondence: Jennifer L. Hsiao, MD, 2020 Santa Monica Blvd, Ste 510, Santa Monica, CA 90404 (Jhsiao@mednet.ucla.edu).

Issue
Cutis - 105(6)
Publications
Topics
Page Number
288, 293
Sections
Author and Disclosure Information

Ms. Patel and Dr. Hsiao are from the Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. Dr. Hsiao also is from the Division of Dermatology. Dr. Harview is from Harbor-UCLA Medical Center Graduate Medical Education, Torrance, California.

The authors report no conflict of interest.  

Correspondence: Jennifer L. Hsiao, MD, 2020 Santa Monica Blvd, Ste 510, Santa Monica, CA 90404 (Jhsiao@mednet.ucla.edu).

Author and Disclosure Information

Ms. Patel and Dr. Hsiao are from the Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles. Dr. Hsiao also is from the Division of Dermatology. Dr. Harview is from Harbor-UCLA Medical Center Graduate Medical Education, Torrance, California.

The authors report no conflict of interest.  

Correspondence: Jennifer L. Hsiao, MD, 2020 Santa Monica Blvd, Ste 510, Santa Monica, CA 90404 (Jhsiao@mednet.ucla.edu).

Article PDF
Article PDF
Related Articles

The Diagnosis: Pseudo-Black Hairy Tongue

Pseudo-black hairy tongue is a benign and painless disorder characterized by transient hyperpigmentation of the tongue with a substance that can be easily scraped off. In this case, the patient's lingual discoloration was secondary to the ingestion of bismuth salicylate. The phenomenon is thought to occur due to a reaction between bismuth and sulfur-containing compounds in the saliva, resulting in the characteristic black substance on the surface of the tongue that nestles between the lingual papillae.1 An associated feature may include black stools. Other etiologic factors involved in pseudo-black hairy tongue include food coloring, tobacco, and other drugs such antibiotics and antidepressants.2  

The differential diagnosis of lingual hyperpigmentation includes lingua villosa nigra (also known as black hairy tongue), pigmented fungiform papillae of the tongue, acanthosis nigricans, and oral hairy leukoplakia. Lingua villosa nigra is a similar condition in which individuals present with a black tongue; however, the tongue also appears hairy. The tongue may appear as other colors such as brown, yellow, or green. Patients additionally may have symptoms of burning, dysgeusia, halitosis, or gagging. Poor oral hygiene, xerostomia, use of tobacco or alcohol, and different medications including antibiotics and antipsychotic medications increase the risk for developing lingua villosa nigra.2,3 This condition is distinguished from pseudo-black hairy tongue by proliferation and elongation of the filiform papillae.3 Pigmented fungiform papillae of the tongue is a normal variant of tongue morphology, is more common in individuals with darker skin types, and primarily affects the lateral aspect and apex of the tongue.4 Acanthosis nigricans can appear in the oral cavity as multiple pigmented papillary lesions on the dorsal and lateral regions of the tongue and frequently involves the lips; this condition may be associated with metabolic disorders or underlying malignancy.2,3 Oral hairy leukoplakia is caused by Epstein-Barr virus infection and typically presents as white plaques on the dorsal and ventral surfaces of the tongue; this condition largely is found in immunocompromised patients.5

In our patient there was an acute onset of tongue discoloration associated with ingestion of bismuth salicylate, no hypertrophy or lengthening of the lingual papillae, and no involvement of the patient's lips, which was consistent with the diagnosis of pseudo-black hairy tongue. Pseudo-black hairy tongue is transient and treated by discontinuation of offending agents and proper hygiene practices.

The Diagnosis: Pseudo-Black Hairy Tongue

Pseudo-black hairy tongue is a benign and painless disorder characterized by transient hyperpigmentation of the tongue with a substance that can be easily scraped off. In this case, the patient's lingual discoloration was secondary to the ingestion of bismuth salicylate. The phenomenon is thought to occur due to a reaction between bismuth and sulfur-containing compounds in the saliva, resulting in the characteristic black substance on the surface of the tongue that nestles between the lingual papillae.1 An associated feature may include black stools. Other etiologic factors involved in pseudo-black hairy tongue include food coloring, tobacco, and other drugs such antibiotics and antidepressants.2  

The differential diagnosis of lingual hyperpigmentation includes lingua villosa nigra (also known as black hairy tongue), pigmented fungiform papillae of the tongue, acanthosis nigricans, and oral hairy leukoplakia. Lingua villosa nigra is a similar condition in which individuals present with a black tongue; however, the tongue also appears hairy. The tongue may appear as other colors such as brown, yellow, or green. Patients additionally may have symptoms of burning, dysgeusia, halitosis, or gagging. Poor oral hygiene, xerostomia, use of tobacco or alcohol, and different medications including antibiotics and antipsychotic medications increase the risk for developing lingua villosa nigra.2,3 This condition is distinguished from pseudo-black hairy tongue by proliferation and elongation of the filiform papillae.3 Pigmented fungiform papillae of the tongue is a normal variant of tongue morphology, is more common in individuals with darker skin types, and primarily affects the lateral aspect and apex of the tongue.4 Acanthosis nigricans can appear in the oral cavity as multiple pigmented papillary lesions on the dorsal and lateral regions of the tongue and frequently involves the lips; this condition may be associated with metabolic disorders or underlying malignancy.2,3 Oral hairy leukoplakia is caused by Epstein-Barr virus infection and typically presents as white plaques on the dorsal and ventral surfaces of the tongue; this condition largely is found in immunocompromised patients.5

In our patient there was an acute onset of tongue discoloration associated with ingestion of bismuth salicylate, no hypertrophy or lengthening of the lingual papillae, and no involvement of the patient's lips, which was consistent with the diagnosis of pseudo-black hairy tongue. Pseudo-black hairy tongue is transient and treated by discontinuation of offending agents and proper hygiene practices.

References
  1. Bradley B, Singleton M, Lin Wan Po A. Bismuth toxicity--a reassessment. J Clin Pharm Ther. 1989;14:423-441.
  2. Gurvits GE, Tan A. Black hairy tongue syndrome. World J Gastroenterol. 2014;20:10845-10850.
  3. Schlager E, St Claire C, Ashack K, et al. Black hairy tongue: predisposing factors, diagnosis, and treatment. Am J Clin Dermatol. 2017;18:563-569.  
  4. Mangold AR, Torgerson RR, Rogers RS. Diseases of the tongue. Clin Dermatol. 2016;34:458-469.
  5. Husak R, Garbe C, Orfanos CE. Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol. 1996;35:928-934.
References
  1. Bradley B, Singleton M, Lin Wan Po A. Bismuth toxicity--a reassessment. J Clin Pharm Ther. 1989;14:423-441.
  2. Gurvits GE, Tan A. Black hairy tongue syndrome. World J Gastroenterol. 2014;20:10845-10850.
  3. Schlager E, St Claire C, Ashack K, et al. Black hairy tongue: predisposing factors, diagnosis, and treatment. Am J Clin Dermatol. 2017;18:563-569.  
  4. Mangold AR, Torgerson RR, Rogers RS. Diseases of the tongue. Clin Dermatol. 2016;34:458-469.
  5. Husak R, Garbe C, Orfanos CE. Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol. 1996;35:928-934.
Issue
Cutis - 105(6)
Issue
Cutis - 105(6)
Page Number
288, 293
Page Number
288, 293
Publications
Publications
Topics
Article Type
Display Headline
Asymptomatic Transient Lingual Hyperpigmentation
Display Headline
Asymptomatic Transient Lingual Hyperpigmentation
Sections
Questionnaire Body

A 77-year-old woman incidentally was noted to have black discoloration of the tongue during a routine dermatologic examination. The patient was unaware of the tongue discoloration and reported that her tongue appeared normal the day prior. The tongue was asymptomatic. Clinical examination revealed black hyperpigmentation on the dorsal aspect of the tongue without appreciable hypertrophy or hyperkeratosis of the filiform papillae. The patient had a half-pack daily smoking habit for many years but had abstained from any smoking or tobacco use for the last 15 years. The patient endorsed good oral hygiene. Upon further questioning, the patient revealed that she had ingested 1 tablet of bismuth salicylate the prior night to relieve postprandial dyspepsia. A cotton-tipped applicator was rubbed gently against the affected area and removed some of the black pigment. 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 06/01/2020 - 16:00
Un-Gate On Date
Mon, 06/01/2020 - 16:00
Use ProPublica
CFC Schedule Remove Status
Mon, 06/01/2020 - 16:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Article PDF Media

A Reticular Rash on the Leg

Article Type
Changed
Thu, 08/08/2019 - 16:11
A man presented with a nontender, flat rash with pigmentary alteration ranging from light brown to dark brown on his left leg. How would you treat this patient?

A 73-year-old male veteran with a history of ischemic stroke with left-sided deficits and edema, falls, poorly controlled hypertension, active tobacco use, obesity, and prediabetes was assessed on a routine visit by our home-based primary care team and found to have a new, unilateral, asymptomatic rash. He reported feeling no pain in the affected area or any significant increase in the baseline left lower extremity edema and weakness resulting from his stroke 2 years prior.

On the left lateral leg from mid-thigh to mid-calf, there was a nontender, flat, reticulated rash with pigmentary alteration ranging from light brown to dark brown (Figure).

On further questioning, the patient reported regular use of a space heater because his gas furnace had been destroyed in an earthquake more than 20 years before. He would place this heater close to his left leg when using the computer or while sleeping in his wheelchair.

  • What is your diagnosis?
  • How would you treat this patient?

 

 

Our Diagnosis

Erythema ab igne, also called hot water bottle rash, is a clinical diagnosis based on characteristic cutaneous findings and a clear history of chronic, moderate heat or infrared exposure.1 Although exposure to space heaters, open fire, radiators, hot water bottles, and heating pads are the classic causes, recently there have been reports of laptop computers, cell phones, infrared food lamps, automobile seat heaters, and heated recliners causing the same type of skin reaction.2

With chronic moderate heat or infrared exposure, the rash usually progresses over days to months. It begins as a mild, transient, reticulated, erythematous rash, which follows the pattern of the cutaneous venous plexus and resolves minutes to hours after removal of the offending source as vasodilation resolves. After months of continued exposure, the dermis around the affected vasculature eventually becomes hyperpigmented due to the deposition of melanin and sometimes hemosiderin.

The rash is usually asymptomatic but has been associated with pain, pruritis, and/or tingling. Once the diagnosis is made, treatment involves removal of the offending source. The discoloration may resolve over months to years, but permanent hyperpigmentation is not uncommon. There are a few case reports on treatment using Nd-Yag laser therapy, topical hydroquinone and tretinoin, 5-fluorouracil, and systemic mesoglycan with topical bioflavonoids.2-4

While the prognosis of erythema ab igne is excellent if detected early, failure to recognize this condition and remove the offending source can lead to sequalae, such as squamous cell carcinoma, poorly differentiated carcinoma, cutaneous marginal zone lymphoma, and Merkel cell carcinoma.5-8 Development of malignancy typically has a latency period of > 30 years. Patients should have periodic surveillance of their skin and any suspicious lesion in the involved area should be considered for biopsy.

Rashes may represent systemic or more localized pathology (Table). In contrast to erythema ab igne, the rash associated with a vasculitic process (autoimmune, drug-induced, or infectious) tends to be more generalized and bilateral but still follows the pattern of the cutaneous venous plexus. An example of this would be livedo reticularis. Although this rash is reticular, it is not hyperpigmented.9 A variant of livedo reticularis is cutis marmorata, which develops in response to cold exposure, particularly in infants or in the setting of hypothyroidism.Cutis marmorata is erythematous, blanchable, and reversible with rewarming. Unlike erythema ab igne, there is no hyperpigmentation and tends to be more diffuse.10 

When evaluating a reticular rash, consider local and systemic etiologies. If more localized and hyperpigmented, ask about heat or infrared exposure. This may point to a diagnosis of erythema ab igne.

References

1. Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5, pt 1):1003-1019.

2. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;162(1):77-78.

3. Kim HW, Kim EJ, Park HC, Ko JY, Ro YS, Kim JE. Erythema ab igne successfully treated with low fluenced 1,064-nm Q-switched Neodymium-Doped Yttrium Aluminum Garnet laser. J Cosmet Laser Ther. 2014;16(3):147-148.

4. Gianfaldoni S, Gianfaldoni R, Tchernev G, Lotti J, Wollina U, Lotti T. Erythema ab igne successfully treated with mesoglycan and bioflavonoids: a case-report. Open Access Maced J Med Sci. 2017;5(4):432-435.

5. Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. AMA Arch Derm. 1979;115(10):1226-1228.

6. Sigmon JR, Cantrell J, Teague D, Sangueza O, Sheehan DJ. Poorly differentiated carcinoma arising in the setting of erythema ab igne. Am J Dermatopathol. 2013;35(6):676-678

7. Wharton J, Roffwarg D, Miller J, Sheehan DJ. Cutaneous marginal zone lymphoma arising in the setting of erythema ab igne. J Am Acad Dermatol. 2010;62(6):1080-1081.

8. Jones CS. Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol. 1988;124(1):110-113.

9. Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J. 2015;6(5):315-321.

10. O’Connor NR, McLaughlin MR, Ham P. Newborn skin: part I. Common rashes. Am Fam Physician. 2008;77(1):47-52.

Article PDF
Author and Disclosure Information

Christina Harview is a Dermatology Resident at the University of Iowa in Iowa City. Mary White is a Home-Based Primary Care Attending Physician and Associate Professor of Medicine, and Sarah Tubbesing is the Medical Director of Home-Based Primary Care and Assistant Professor of Medicine; both at the VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California, Los Angeles.
Correspondence: Mary White (mary.white3@va.gov)

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Issue
Federal Practitioner - 36(8)a
Publications
Topics
Page Number
385-386
Sections
Author and Disclosure Information

Christina Harview is a Dermatology Resident at the University of Iowa in Iowa City. Mary White is a Home-Based Primary Care Attending Physician and Associate Professor of Medicine, and Sarah Tubbesing is the Medical Director of Home-Based Primary Care and Assistant Professor of Medicine; both at the VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California, Los Angeles.
Correspondence: Mary White (mary.white3@va.gov)

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Author and Disclosure Information

Christina Harview is a Dermatology Resident at the University of Iowa in Iowa City. Mary White is a Home-Based Primary Care Attending Physician and Associate Professor of Medicine, and Sarah Tubbesing is the Medical Director of Home-Based Primary Care and Assistant Professor of Medicine; both at the VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California, Los Angeles.
Correspondence: Mary White (mary.white3@va.gov)

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Article PDF
Article PDF
Related Articles
A man presented with a nontender, flat rash with pigmentary alteration ranging from light brown to dark brown on his left leg. How would you treat this patient?
A man presented with a nontender, flat rash with pigmentary alteration ranging from light brown to dark brown on his left leg. How would you treat this patient?

A 73-year-old male veteran with a history of ischemic stroke with left-sided deficits and edema, falls, poorly controlled hypertension, active tobacco use, obesity, and prediabetes was assessed on a routine visit by our home-based primary care team and found to have a new, unilateral, asymptomatic rash. He reported feeling no pain in the affected area or any significant increase in the baseline left lower extremity edema and weakness resulting from his stroke 2 years prior.

On the left lateral leg from mid-thigh to mid-calf, there was a nontender, flat, reticulated rash with pigmentary alteration ranging from light brown to dark brown (Figure).

On further questioning, the patient reported regular use of a space heater because his gas furnace had been destroyed in an earthquake more than 20 years before. He would place this heater close to his left leg when using the computer or while sleeping in his wheelchair.

  • What is your diagnosis?
  • How would you treat this patient?

 

 

Our Diagnosis

Erythema ab igne, also called hot water bottle rash, is a clinical diagnosis based on characteristic cutaneous findings and a clear history of chronic, moderate heat or infrared exposure.1 Although exposure to space heaters, open fire, radiators, hot water bottles, and heating pads are the classic causes, recently there have been reports of laptop computers, cell phones, infrared food lamps, automobile seat heaters, and heated recliners causing the same type of skin reaction.2

With chronic moderate heat or infrared exposure, the rash usually progresses over days to months. It begins as a mild, transient, reticulated, erythematous rash, which follows the pattern of the cutaneous venous plexus and resolves minutes to hours after removal of the offending source as vasodilation resolves. After months of continued exposure, the dermis around the affected vasculature eventually becomes hyperpigmented due to the deposition of melanin and sometimes hemosiderin.

The rash is usually asymptomatic but has been associated with pain, pruritis, and/or tingling. Once the diagnosis is made, treatment involves removal of the offending source. The discoloration may resolve over months to years, but permanent hyperpigmentation is not uncommon. There are a few case reports on treatment using Nd-Yag laser therapy, topical hydroquinone and tretinoin, 5-fluorouracil, and systemic mesoglycan with topical bioflavonoids.2-4

While the prognosis of erythema ab igne is excellent if detected early, failure to recognize this condition and remove the offending source can lead to sequalae, such as squamous cell carcinoma, poorly differentiated carcinoma, cutaneous marginal zone lymphoma, and Merkel cell carcinoma.5-8 Development of malignancy typically has a latency period of > 30 years. Patients should have periodic surveillance of their skin and any suspicious lesion in the involved area should be considered for biopsy.

Rashes may represent systemic or more localized pathology (Table). In contrast to erythema ab igne, the rash associated with a vasculitic process (autoimmune, drug-induced, or infectious) tends to be more generalized and bilateral but still follows the pattern of the cutaneous venous plexus. An example of this would be livedo reticularis. Although this rash is reticular, it is not hyperpigmented.9 A variant of livedo reticularis is cutis marmorata, which develops in response to cold exposure, particularly in infants or in the setting of hypothyroidism.Cutis marmorata is erythematous, blanchable, and reversible with rewarming. Unlike erythema ab igne, there is no hyperpigmentation and tends to be more diffuse.10 

When evaluating a reticular rash, consider local and systemic etiologies. If more localized and hyperpigmented, ask about heat or infrared exposure. This may point to a diagnosis of erythema ab igne.

A 73-year-old male veteran with a history of ischemic stroke with left-sided deficits and edema, falls, poorly controlled hypertension, active tobacco use, obesity, and prediabetes was assessed on a routine visit by our home-based primary care team and found to have a new, unilateral, asymptomatic rash. He reported feeling no pain in the affected area or any significant increase in the baseline left lower extremity edema and weakness resulting from his stroke 2 years prior.

On the left lateral leg from mid-thigh to mid-calf, there was a nontender, flat, reticulated rash with pigmentary alteration ranging from light brown to dark brown (Figure).

On further questioning, the patient reported regular use of a space heater because his gas furnace had been destroyed in an earthquake more than 20 years before. He would place this heater close to his left leg when using the computer or while sleeping in his wheelchair.

  • What is your diagnosis?
  • How would you treat this patient?

 

 

Our Diagnosis

Erythema ab igne, also called hot water bottle rash, is a clinical diagnosis based on characteristic cutaneous findings and a clear history of chronic, moderate heat or infrared exposure.1 Although exposure to space heaters, open fire, radiators, hot water bottles, and heating pads are the classic causes, recently there have been reports of laptop computers, cell phones, infrared food lamps, automobile seat heaters, and heated recliners causing the same type of skin reaction.2

With chronic moderate heat or infrared exposure, the rash usually progresses over days to months. It begins as a mild, transient, reticulated, erythematous rash, which follows the pattern of the cutaneous venous plexus and resolves minutes to hours after removal of the offending source as vasodilation resolves. After months of continued exposure, the dermis around the affected vasculature eventually becomes hyperpigmented due to the deposition of melanin and sometimes hemosiderin.

The rash is usually asymptomatic but has been associated with pain, pruritis, and/or tingling. Once the diagnosis is made, treatment involves removal of the offending source. The discoloration may resolve over months to years, but permanent hyperpigmentation is not uncommon. There are a few case reports on treatment using Nd-Yag laser therapy, topical hydroquinone and tretinoin, 5-fluorouracil, and systemic mesoglycan with topical bioflavonoids.2-4

While the prognosis of erythema ab igne is excellent if detected early, failure to recognize this condition and remove the offending source can lead to sequalae, such as squamous cell carcinoma, poorly differentiated carcinoma, cutaneous marginal zone lymphoma, and Merkel cell carcinoma.5-8 Development of malignancy typically has a latency period of > 30 years. Patients should have periodic surveillance of their skin and any suspicious lesion in the involved area should be considered for biopsy.

Rashes may represent systemic or more localized pathology (Table). In contrast to erythema ab igne, the rash associated with a vasculitic process (autoimmune, drug-induced, or infectious) tends to be more generalized and bilateral but still follows the pattern of the cutaneous venous plexus. An example of this would be livedo reticularis. Although this rash is reticular, it is not hyperpigmented.9 A variant of livedo reticularis is cutis marmorata, which develops in response to cold exposure, particularly in infants or in the setting of hypothyroidism.Cutis marmorata is erythematous, blanchable, and reversible with rewarming. Unlike erythema ab igne, there is no hyperpigmentation and tends to be more diffuse.10 

When evaluating a reticular rash, consider local and systemic etiologies. If more localized and hyperpigmented, ask about heat or infrared exposure. This may point to a diagnosis of erythema ab igne.

References

1. Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5, pt 1):1003-1019.

2. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;162(1):77-78.

3. Kim HW, Kim EJ, Park HC, Ko JY, Ro YS, Kim JE. Erythema ab igne successfully treated with low fluenced 1,064-nm Q-switched Neodymium-Doped Yttrium Aluminum Garnet laser. J Cosmet Laser Ther. 2014;16(3):147-148.

4. Gianfaldoni S, Gianfaldoni R, Tchernev G, Lotti J, Wollina U, Lotti T. Erythema ab igne successfully treated with mesoglycan and bioflavonoids: a case-report. Open Access Maced J Med Sci. 2017;5(4):432-435.

5. Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. AMA Arch Derm. 1979;115(10):1226-1228.

6. Sigmon JR, Cantrell J, Teague D, Sangueza O, Sheehan DJ. Poorly differentiated carcinoma arising in the setting of erythema ab igne. Am J Dermatopathol. 2013;35(6):676-678

7. Wharton J, Roffwarg D, Miller J, Sheehan DJ. Cutaneous marginal zone lymphoma arising in the setting of erythema ab igne. J Am Acad Dermatol. 2010;62(6):1080-1081.

8. Jones CS. Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol. 1988;124(1):110-113.

9. Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J. 2015;6(5):315-321.

10. O’Connor NR, McLaughlin MR, Ham P. Newborn skin: part I. Common rashes. Am Fam Physician. 2008;77(1):47-52.

References

1. Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5, pt 1):1003-1019.

2. Tan S, Bertucci V. Erythema ab igne: an old condition new again. CMAJ. 2000;162(1):77-78.

3. Kim HW, Kim EJ, Park HC, Ko JY, Ro YS, Kim JE. Erythema ab igne successfully treated with low fluenced 1,064-nm Q-switched Neodymium-Doped Yttrium Aluminum Garnet laser. J Cosmet Laser Ther. 2014;16(3):147-148.

4. Gianfaldoni S, Gianfaldoni R, Tchernev G, Lotti J, Wollina U, Lotti T. Erythema ab igne successfully treated with mesoglycan and bioflavonoids: a case-report. Open Access Maced J Med Sci. 2017;5(4):432-435.

5. Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. AMA Arch Derm. 1979;115(10):1226-1228.

6. Sigmon JR, Cantrell J, Teague D, Sangueza O, Sheehan DJ. Poorly differentiated carcinoma arising in the setting of erythema ab igne. Am J Dermatopathol. 2013;35(6):676-678

7. Wharton J, Roffwarg D, Miller J, Sheehan DJ. Cutaneous marginal zone lymphoma arising in the setting of erythema ab igne. J Am Acad Dermatol. 2010;62(6):1080-1081.

8. Jones CS. Development of neuroendocrine (Merkel cell) carcinoma mixed with squamous cell carcinoma in erythema ab igne. Arch Dermatol. 1988;124(1):110-113.

9. Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J. 2015;6(5):315-321.

10. O’Connor NR, McLaughlin MR, Ham P. Newborn skin: part I. Common rashes. Am Fam Physician. 2008;77(1):47-52.

Issue
Federal Practitioner - 36(8)a
Issue
Federal Practitioner - 36(8)a
Page Number
385-386
Page Number
385-386
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Rapidly growing lesions on the forehead

Article Type
Changed
Wed, 07/10/2019 - 12:25
Display Headline
Rapidly growing lesions on the forehead

A 97-year-old woman with a history of atrial fibrillation and nonmelanoma skin cancer presented to our clinic from an assisted living facility with a several-month history of rapidly growing forehead lesions. She denied symptoms, other than some bleeding and crusting, but was concerned about their appearance. She reported a notable history of sun exposure.

The patient had 3 confluent, but distinct, lesions on her forehead: an erythematous crateriform nodule with overlying hyperkeratotic scale (FIGURE, Lesion A); a nodular hyperpigmented plaque with irregular color and borders (Lesion B); and a pearly well-vascularized erythematous nodule with surrounding hemorrhagic crust (Lesion C).

Three large lesions on forehead with erythematous papules, plaques on face

She also had scattered, thin, gritty pink papules and plaques on the face that were thought to be actinic keratosis and nonmelanoma skin cancers based on clinical morphology; however, the patient deferred workup and treatment of these lesions to focus on the forehead lesions. The decision was made to biopsy all 3 clinical morphologies seen. The risks and benefits of biopsy were reviewed with the patient and her daughter, and they opted to proceed. The areas were anesthetized with an injection of 1% lidocaine and epinephrine 1:100,000; 3 shave biopsies were performed. Hemostasis was obtained with electrodesiccation.

WHAT IS YOUR DIAGNOSIS?
HOW WOULD YOU TREAT THIS PATIENT?

 

 

Diagnosis: Skin cancer

A histopathology report revealed that Lesion A was squamous cell carcinoma (SCC), Lesion B was a melanoma with a Breslow depth of at least 1.2 mm, and Lesion C was basal cell carcinoma (BCC). It is unusual to have a patient present with BCC, SCC, and melanoma concurrently in the same anatomic region.

Two of the lesions were nonmelanoma skin cancers (NMSC). BCC is the most common NMSC in the United States, affecting more than 3.3 million people per year.1 Although there are several subtypes of BCC with varying clinical presentations, the most classic appearance is a pearly papule with or without surface telangiectasias.2

The findings in this case serve as an important reminder to biopsy lesions with varying morphologies even when they are in close proximity to one another.

SCC has an incidence of 200,000 to 400,000 cases per year in the United States and the lifetime risk is 9% to 14% in men and 4% to 9% in women.3 SCC most commonly presents as a hyperkeratotic papule or plaque.2 Lesions suspicious for SCC and BCC should be biopsied and the diagnosis confirmed by histopathologic analysis. These NMSCs are locally destructive, but rarely metastatic with a generally good prognosis. The standard treatment for both is surgical excision with consideration for other treatment modalities, such as topical therapies, chemotherapy, and radiation, depending on tumor characteristics as well as whether the patient is a good surgical candidate.1,3

 

Melanoma is rising in incidence each year, with nearly 100,000 new cases expected in the United States this year.4 It is the leading cause of skin cancer related mortality.5 The most common suspicious lesions are variably pigmented macules with irregular borders. Biopsy and subsequent histopathologic analysis will confirm the diagnosis.

When a lesion is clinically suspicious for melanoma, it is particularly important to consider an excisional biopsy to allow for proper staging.5 Examples of appropriate excisional biopsies include elliptical excisions, punch biopsies, and deep shave biopsies.5 Definitive treatment involves a wider and deeper excision with histologically confirmed clear margins.5

Continue to: This case required a multidisciplinary team

 

 

This case required a multidisciplinary team

The patient underwent magnetic resonance imaging and positron emission tomography/computed tomography; the scans revealed no metastatic disease. She was evaluated by a multidisciplinary head and neck cancer team, and various treatment options were explored. Resection typically is the definitive treatment for localized cutaneous melanoma; however, given the configuration of the lesions, it was deemed impractical to resect this patient’s melanoma and not the other lesions. Radiotherapy can be effective for BCC and SCC, but it is traditionally not as effective for melanoma.6 The options presented to the patient were radiotherapy or surgical resection to all 3 lesions, and she decided to pursue resection.

The patient was cleared for surgery; however, after the patient held her warfarin in preparation for the resection, she suffered a left frontal operculum infarction. At this point, she was re-evaluated by her head and neck physician, cardiologist, and anesthesiologist. Consensus was reached that the patient was at high perioperative risk for morbidity and mortality, and surgical intervention was no longer considered a viable option.

The patient then opted for palliative radiation therapy to all 3 lesions, with the understanding that the local control offered by radiotherapy would be inferior to what resection would provide for the melanoma lesion. Although not curative, radiotherapy was expected to provide local symptom relief for the melanoma, consistent with the patient’s palliative goals of care. In the past, melanoma was thought to be resistant to radiation, but recent evidence suggests that it may be at least partially susceptible to hypofractionated courses of radiation.6

Radiation oncology recommended a 6 to 15 fraction regimen and she had a good clinical response with > 50% decrease in the size of all 3 lesions along with cessation of bleeding.

The take-home lesson. The findings in this case serve as an important reminder to biopsy lesions with varying morphologies—even when they are in close proximity to one another. Foregoing any of the biopsies in this case would have led to a missed diagnosis, which has implications for optimal management and treatment.

CORRESPONDENCE
Jennifer L. Hsiao, MD, 2020 Santa Monica Boulevard, Suite 510, Santa Monica, CA 90404; jhsiao@mednet.ucla.edu

References

1. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78:540-559.

2. Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician. 2012;86:161-168.

3. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-578.

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.

5. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250.

6. Vuong W, Lin J, Wei RL. Palliative radiotherapy for skin malignancies. Ann Palliat Med. 2017;6:165-172.

Article PDF
Author and Disclosure Information

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles
jhsiao@mednet.ucla.edu

DEPARTMENT EDITOR
Richard P. Usatine, MD

University of Texas Health at San Antonio

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 68(5)
Publications
Topics
Page Number
293-295
Sections
Author and Disclosure Information

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles
jhsiao@mednet.ucla.edu

DEPARTMENT EDITOR
Richard P. Usatine, MD

University of Texas Health at San Antonio

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles
jhsiao@mednet.ucla.edu

DEPARTMENT EDITOR
Richard P. Usatine, MD

University of Texas Health at San Antonio

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF

A 97-year-old woman with a history of atrial fibrillation and nonmelanoma skin cancer presented to our clinic from an assisted living facility with a several-month history of rapidly growing forehead lesions. She denied symptoms, other than some bleeding and crusting, but was concerned about their appearance. She reported a notable history of sun exposure.

The patient had 3 confluent, but distinct, lesions on her forehead: an erythematous crateriform nodule with overlying hyperkeratotic scale (FIGURE, Lesion A); a nodular hyperpigmented plaque with irregular color and borders (Lesion B); and a pearly well-vascularized erythematous nodule with surrounding hemorrhagic crust (Lesion C).

Three large lesions on forehead with erythematous papules, plaques on face

She also had scattered, thin, gritty pink papules and plaques on the face that were thought to be actinic keratosis and nonmelanoma skin cancers based on clinical morphology; however, the patient deferred workup and treatment of these lesions to focus on the forehead lesions. The decision was made to biopsy all 3 clinical morphologies seen. The risks and benefits of biopsy were reviewed with the patient and her daughter, and they opted to proceed. The areas were anesthetized with an injection of 1% lidocaine and epinephrine 1:100,000; 3 shave biopsies were performed. Hemostasis was obtained with electrodesiccation.

WHAT IS YOUR DIAGNOSIS?
HOW WOULD YOU TREAT THIS PATIENT?

 

 

Diagnosis: Skin cancer

A histopathology report revealed that Lesion A was squamous cell carcinoma (SCC), Lesion B was a melanoma with a Breslow depth of at least 1.2 mm, and Lesion C was basal cell carcinoma (BCC). It is unusual to have a patient present with BCC, SCC, and melanoma concurrently in the same anatomic region.

Two of the lesions were nonmelanoma skin cancers (NMSC). BCC is the most common NMSC in the United States, affecting more than 3.3 million people per year.1 Although there are several subtypes of BCC with varying clinical presentations, the most classic appearance is a pearly papule with or without surface telangiectasias.2

The findings in this case serve as an important reminder to biopsy lesions with varying morphologies even when they are in close proximity to one another.

SCC has an incidence of 200,000 to 400,000 cases per year in the United States and the lifetime risk is 9% to 14% in men and 4% to 9% in women.3 SCC most commonly presents as a hyperkeratotic papule or plaque.2 Lesions suspicious for SCC and BCC should be biopsied and the diagnosis confirmed by histopathologic analysis. These NMSCs are locally destructive, but rarely metastatic with a generally good prognosis. The standard treatment for both is surgical excision with consideration for other treatment modalities, such as topical therapies, chemotherapy, and radiation, depending on tumor characteristics as well as whether the patient is a good surgical candidate.1,3

 

Melanoma is rising in incidence each year, with nearly 100,000 new cases expected in the United States this year.4 It is the leading cause of skin cancer related mortality.5 The most common suspicious lesions are variably pigmented macules with irregular borders. Biopsy and subsequent histopathologic analysis will confirm the diagnosis.

When a lesion is clinically suspicious for melanoma, it is particularly important to consider an excisional biopsy to allow for proper staging.5 Examples of appropriate excisional biopsies include elliptical excisions, punch biopsies, and deep shave biopsies.5 Definitive treatment involves a wider and deeper excision with histologically confirmed clear margins.5

Continue to: This case required a multidisciplinary team

 

 

This case required a multidisciplinary team

The patient underwent magnetic resonance imaging and positron emission tomography/computed tomography; the scans revealed no metastatic disease. She was evaluated by a multidisciplinary head and neck cancer team, and various treatment options were explored. Resection typically is the definitive treatment for localized cutaneous melanoma; however, given the configuration of the lesions, it was deemed impractical to resect this patient’s melanoma and not the other lesions. Radiotherapy can be effective for BCC and SCC, but it is traditionally not as effective for melanoma.6 The options presented to the patient were radiotherapy or surgical resection to all 3 lesions, and she decided to pursue resection.

The patient was cleared for surgery; however, after the patient held her warfarin in preparation for the resection, she suffered a left frontal operculum infarction. At this point, she was re-evaluated by her head and neck physician, cardiologist, and anesthesiologist. Consensus was reached that the patient was at high perioperative risk for morbidity and mortality, and surgical intervention was no longer considered a viable option.

The patient then opted for palliative radiation therapy to all 3 lesions, with the understanding that the local control offered by radiotherapy would be inferior to what resection would provide for the melanoma lesion. Although not curative, radiotherapy was expected to provide local symptom relief for the melanoma, consistent with the patient’s palliative goals of care. In the past, melanoma was thought to be resistant to radiation, but recent evidence suggests that it may be at least partially susceptible to hypofractionated courses of radiation.6

Radiation oncology recommended a 6 to 15 fraction regimen and she had a good clinical response with > 50% decrease in the size of all 3 lesions along with cessation of bleeding.

The take-home lesson. The findings in this case serve as an important reminder to biopsy lesions with varying morphologies—even when they are in close proximity to one another. Foregoing any of the biopsies in this case would have led to a missed diagnosis, which has implications for optimal management and treatment.

CORRESPONDENCE
Jennifer L. Hsiao, MD, 2020 Santa Monica Boulevard, Suite 510, Santa Monica, CA 90404; jhsiao@mednet.ucla.edu

A 97-year-old woman with a history of atrial fibrillation and nonmelanoma skin cancer presented to our clinic from an assisted living facility with a several-month history of rapidly growing forehead lesions. She denied symptoms, other than some bleeding and crusting, but was concerned about their appearance. She reported a notable history of sun exposure.

The patient had 3 confluent, but distinct, lesions on her forehead: an erythematous crateriform nodule with overlying hyperkeratotic scale (FIGURE, Lesion A); a nodular hyperpigmented plaque with irregular color and borders (Lesion B); and a pearly well-vascularized erythematous nodule with surrounding hemorrhagic crust (Lesion C).

Three large lesions on forehead with erythematous papules, plaques on face

She also had scattered, thin, gritty pink papules and plaques on the face that were thought to be actinic keratosis and nonmelanoma skin cancers based on clinical morphology; however, the patient deferred workup and treatment of these lesions to focus on the forehead lesions. The decision was made to biopsy all 3 clinical morphologies seen. The risks and benefits of biopsy were reviewed with the patient and her daughter, and they opted to proceed. The areas were anesthetized with an injection of 1% lidocaine and epinephrine 1:100,000; 3 shave biopsies were performed. Hemostasis was obtained with electrodesiccation.

WHAT IS YOUR DIAGNOSIS?
HOW WOULD YOU TREAT THIS PATIENT?

 

 

Diagnosis: Skin cancer

A histopathology report revealed that Lesion A was squamous cell carcinoma (SCC), Lesion B was a melanoma with a Breslow depth of at least 1.2 mm, and Lesion C was basal cell carcinoma (BCC). It is unusual to have a patient present with BCC, SCC, and melanoma concurrently in the same anatomic region.

Two of the lesions were nonmelanoma skin cancers (NMSC). BCC is the most common NMSC in the United States, affecting more than 3.3 million people per year.1 Although there are several subtypes of BCC with varying clinical presentations, the most classic appearance is a pearly papule with or without surface telangiectasias.2

The findings in this case serve as an important reminder to biopsy lesions with varying morphologies even when they are in close proximity to one another.

SCC has an incidence of 200,000 to 400,000 cases per year in the United States and the lifetime risk is 9% to 14% in men and 4% to 9% in women.3 SCC most commonly presents as a hyperkeratotic papule or plaque.2 Lesions suspicious for SCC and BCC should be biopsied and the diagnosis confirmed by histopathologic analysis. These NMSCs are locally destructive, but rarely metastatic with a generally good prognosis. The standard treatment for both is surgical excision with consideration for other treatment modalities, such as topical therapies, chemotherapy, and radiation, depending on tumor characteristics as well as whether the patient is a good surgical candidate.1,3

 

Melanoma is rising in incidence each year, with nearly 100,000 new cases expected in the United States this year.4 It is the leading cause of skin cancer related mortality.5 The most common suspicious lesions are variably pigmented macules with irregular borders. Biopsy and subsequent histopathologic analysis will confirm the diagnosis.

When a lesion is clinically suspicious for melanoma, it is particularly important to consider an excisional biopsy to allow for proper staging.5 Examples of appropriate excisional biopsies include elliptical excisions, punch biopsies, and deep shave biopsies.5 Definitive treatment involves a wider and deeper excision with histologically confirmed clear margins.5

Continue to: This case required a multidisciplinary team

 

 

This case required a multidisciplinary team

The patient underwent magnetic resonance imaging and positron emission tomography/computed tomography; the scans revealed no metastatic disease. She was evaluated by a multidisciplinary head and neck cancer team, and various treatment options were explored. Resection typically is the definitive treatment for localized cutaneous melanoma; however, given the configuration of the lesions, it was deemed impractical to resect this patient’s melanoma and not the other lesions. Radiotherapy can be effective for BCC and SCC, but it is traditionally not as effective for melanoma.6 The options presented to the patient were radiotherapy or surgical resection to all 3 lesions, and she decided to pursue resection.

The patient was cleared for surgery; however, after the patient held her warfarin in preparation for the resection, she suffered a left frontal operculum infarction. At this point, she was re-evaluated by her head and neck physician, cardiologist, and anesthesiologist. Consensus was reached that the patient was at high perioperative risk for morbidity and mortality, and surgical intervention was no longer considered a viable option.

The patient then opted for palliative radiation therapy to all 3 lesions, with the understanding that the local control offered by radiotherapy would be inferior to what resection would provide for the melanoma lesion. Although not curative, radiotherapy was expected to provide local symptom relief for the melanoma, consistent with the patient’s palliative goals of care. In the past, melanoma was thought to be resistant to radiation, but recent evidence suggests that it may be at least partially susceptible to hypofractionated courses of radiation.6

Radiation oncology recommended a 6 to 15 fraction regimen and she had a good clinical response with > 50% decrease in the size of all 3 lesions along with cessation of bleeding.

The take-home lesson. The findings in this case serve as an important reminder to biopsy lesions with varying morphologies—even when they are in close proximity to one another. Foregoing any of the biopsies in this case would have led to a missed diagnosis, which has implications for optimal management and treatment.

CORRESPONDENCE
Jennifer L. Hsiao, MD, 2020 Santa Monica Boulevard, Suite 510, Santa Monica, CA 90404; jhsiao@mednet.ucla.edu

References

1. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78:540-559.

2. Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician. 2012;86:161-168.

3. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-578.

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.

5. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250.

6. Vuong W, Lin J, Wei RL. Palliative radiotherapy for skin malignancies. Ann Palliat Med. 2017;6:165-172.

References

1. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78:540-559.

2. Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician. 2012;86:161-168.

3. Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-578.

4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.

5. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208-250.

6. Vuong W, Lin J, Wei RL. Palliative radiotherapy for skin malignancies. Ann Palliat Med. 2017;6:165-172.

Issue
The Journal of Family Practice - 68(5)
Issue
The Journal of Family Practice - 68(5)
Page Number
293-295
Page Number
293-295
Publications
Publications
Topics
Article Type
Display Headline
Rapidly growing lesions on the forehead
Display Headline
Rapidly growing lesions on the forehead
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
PubMed ID
31287446
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media